THE ROLE OF PAK1 IN THE CELLULAR AND MOLECULAR COMPONENTS OF PLEXIFORM NEUROFIBROMAS

Andrew S. McDaniel

Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree Doctor of Philosophy in the Department of Microbiology and Immunology, Indiana University

September 2008
Accepted by the Faculty of Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy.

D. Wade Clapp, M.D., Chair

Hal E. Broxmeyer, Ph.D.

Doctoral Committee

David A. Ingram, M.D.

July 3, 2008

Edward F. Sroul, Ph.D.
ACKNOWLEDGMENTS

I would like to thank each of the members of my thesis committee, who have provided me with excellent advice, direction, and support for four years. It has been so appreciated that scientists of such international stature have made my education a priority.

I would like to thank the faculty and staff of the Department of Microbiology and Immunology, for their time and resources that allowed me the opportunity to pursue this degree. I would also like to thank the advisors, staff, and fellow students of the M.D./Ph.D. program, with whom I have forged lifelong relationships.

I would like to thank the many members of the Clapp laboratory, past and present. There are too many to list but each one has provided me with assistance, insight, camaraderie, and support.

I would especially like to thank Dr. Wade Clapp for his mentorship. Working with Wade has been an experience that has shaped me in ways far more profound than my ability to formulate testable hypothesis and generate publishable data. I am privileged to consider him a friend and anticipate eagerly our scientific and personal interactions for many years to come.

I would like to thank my family for providing me with all the love and guidance any person could desire. The love and admiration I have for my parents, Robert and Anna, and brothers, Matthew and Patrick, is beyond my capabilities for description.

Finally, I would like to thank my wife Sarah. She is my best friend and most ardent supporter, and an exceptional scientific mind. Life without her love and companionship is simply unimaginable.
ABSTRACT

Andrew S. McDaniel

THE ROLE OF PAK1 IN THE CELLULAR AND MOLECULAR COMPONENTS OF PLEXIFORM NEUROFIBROMAS

Neurofibromatosis type I (NF1) is a common genetic disease that affects over 200,000 patients in North America, Europe, and Japan. Individuals with NF1 display a wide variety of pathologies; importantly, 15-40% of NF1 patients are affected by plexiform neurofibromas. Neurofibromas are complex tumors consisting of tumorigenic Schwann cells surrounded by endothelial cells, fibroblasts, and inflammatory mast cells. These peripheral nerve sheath tumors contribute significantly to the morbidity and mortality associated with NF1. Currently, no medical therapies exist for treating neurofibromas. Recent evidence indicates that the hematopoietic tumor microenvironment carries out a crucial function in the formation of plexiform neurofibromas. Neurofibromatosis is the result of mutations at the NF1 locus, which encodes the GTPase activating protein neurofibromin. Neurofibromin is a negative regulator of the proto-oncogene Ras. Ras hyperactivation is the molecular basis of NF1 associated phenotypes, and it has been demonstrated that restoration of Ras signaling to wild type levels can correct NF1 associated phenotypes in vitro and in vivo. In keeping with the long term goal of detecting potential molecular targets for medical therapies to treat human plexiform neurofibromas, we have identified the kinase Pak1 as a possible downstream intermediary of Ras signaling in NF1 deficient cells. Studies described here
utilized murine genetic models to study the effects of genetic inactivation of *Pak1* on molecular signaling and cellular functions related to neurofibromas. We demonstrate that inactivation of *Pak1* leads to correction of SCF mediated gain-in-function phenotypes seen in Nfl haploinsufficient mast cells, *in vivo* and *in vitro*. However, by using a conditional Nfl knockout mouse that is a reliable model of plexiform neurofibroma formation, we shown that loss of *Pak1* alone in the hematopoietic compartement is not sufficient to prevent neurofibroma formation. Additionally, we describe a key role for Pak1 in regulating PDGF and TGF-β mediated fibroblast functions, *in vitro* and *in vivo*. These studies provide insight into the causes of debilitating tumors related to a common genetic disease, and this research could potentially lead to the development of medical therapies for these tumors, increasing the quality of life for tens of thousands of affected individuals each year.

D. Wade Clapp, M.D., Chair
TABLE OF CONTENTS

ABBREVIATIONS........................................................................................................... x

INTRODUCTION........................................................................................................... 1

Disease manifestations of neurofibromatosis type 1 ............................. 1
Genetic basis of neurofibromatosis type 1 ........................................... 3
Murine models of neurofibromatosis type 1 ........................................... 4
Role of mast cells in neurofibroma formation ................................. 6
Fibroblasts contribute to neurofibroma pathology ...................... 9
Ras hyperactivation: the molecular basis of NF1 ....................... 10
Signaling pathways disrupted in the absence of neurofibromin ...... 11
p21 activated kinases: downstream effectors of Rho GTPases ...... 12
Pak1 is a multifunctional signal transducer ............................... 18
Cancer and Pak1 ...................................................................................... 20
Thesis overview ...................................................................................... 21

MATERIALS AND METHODS ........................................................................... 25

Animals.............................................................................................................. 25
Bone marrow mast cell culture .............................................................. 25
Mast cell progenitor assay .................................................................. 26
Mast cell maturation ............................................................................ 26
Mast cell immunoblotting ................................................................. 27
Mast cell proliferation assay .............................................................. 27
Mast cell haptotaxis assay ................................................................. 28
F-actin quantitation ............................................................................. 29
Confocal microscopy ................................................................. 29
Mast cell degranulation assay ......................................................... 30
Mast cell survival assay ................................................................. 30
In vivo mast cell accumulation assay ............................................... 31
Nf1 conditional knockout adoptive transfer ......................................... 32
Generation of Krox20Cre;Nf1flox/-;Pak1-/- animals .......................... 32
Dorsal root ganglion dissection and measurement .............................. 32
Histological analysis of dorsal root ganglia ....................................... 33
Generation and culture of primary fibroblasts ................................. 33
Fibroblast proliferation assay ......................................................... 34
Fibroblast wound healing assay ...................................................... 34
Fibroblast collagen production assay .............................................. 35
Fibroblast apoptosis assay ............................................................. 35
Confocal analysis of fibroblast actin cytoskeleton ............................... 36
Fibroblast immunoblotting ............................................................. 36
In vivo fibroblast invasion assays ..................................................... 37
Bleomycin induced pulmonary fibrosis model ................................... 37

RESULTS .......................................................................................... 39

Role of Pak1 in regulating stem cell factor dependent functions in Nf1 haploinsufficient mast cells .................................................. 39

Generation of a Pak1 knockout mouse ............................................ 39
Intercross of Nf1+/− and Pak1+/− mice ............................................. 42
Loss of Pak1 reduces number of mast cell colonies ......................... 42
Loss of Pak1 does not affect expression of mast cell maturation
markers........................................................................................................................................47

Hyperproliferation of \( Nf1^{+/−} \) bone marrow derived mast cells is dependent on a Pak1/MAPK pathway ..................................................47

Loss of \( Pak1 \) corrects MAPK hyperactivation in \( Nf1 \) haploinsufficient BMMCs..................................................................................................................50

A Pak1/p38 pathway regulates increased migration of \( Nf1^{+/−} \) mast cells..........................................................................................................................60

\( Pak1 \) is required for the increase in p38 phosphorylation seen in \( Nf1 \) haploinsufficient mast cells.................................................................61

\( Pak1 \) regulates F-actin content and organization in a p38-dependent manner..........................................................................................................................66

Disruption of \( Pak1 \) reduces granule release from \( Nf1^{+/−} \) mast cells........67

Loss of \( Pak1 \) does not significantly affect mast cell survival......................71

Cutaneous expansion and degranulation in \( Nf1^{+/−} \) mice in response to SCF is \( Pak1 \) dependent......................................................................................76

**Role of Pak1 in plexiform neurofibroma formation** ........................................84

Adoptive transfer of \( Nf1^{+/−};Pak1^{−/−} \) bone marrow into Schwann cell nullizygous recipients ..................................................................................................................84

\( Krox20Cre:Nf1^{fluox/flax} \) mice reconstituted with \( Nf1^{+/−};Pak1^{−/−} \) bone marrow develop neurofibromas ..................................................87

\( Krox20Cre:Nf1^{fluox/−} \) mice reconstituted with \( Nf1^{+/−};Pak1^{−/−} \) bone marrow develop neurofibromas .................................................................97

Genetic disruption of \( Pak1 \) in \( Krox20Cre:Nf1^{fluox/−} \) mice does not prevent neurofibroma formation .........................................................................................98

**Role of Pak1 in mediating PDGF-BB and TGF-β dependent functions in fibroblasts** ........................................................................................................118

PDGF-BB mediated fibroblast proliferation is \( Pak1 \) dependent ........118

Loss of \( Pak1 \) does not affect TGF-β induced fibroblast proliferation.....125

\( Pak1 \) deficient fibroblasts have reduced migration following
PDGF-BB stimulation........................................................................................................125

Disruptions of PDGF-BB mediated activation of the actin cytoskeleton and associated signaling networks are found in Pak1^{-/-} fibroblasts........128

Loss of Pak1 decreases TGF-β dependent fibroblast migration..............137

TGF-β stimulated fibroblasts have decreased activation of filamin A and disrupted actin cytoskeletal networks ........................................137

Pak1^{-/-} fibroblasts have reduced collagen synthesis in response to TGF-β .................................................................138

Reduced survival of Pak1 null fibroblasts in response to TGF-β and PDGF-BB.................................................................149

Loss of Pak1 inhibits fibroblast recruitment in vivo ..................................149

Genetic disruption of Pak1 reduces the severity of bleomycin induced lung fibrosis.................................................................152

DISCUSSION ............................................................................................................164

Role of Pak1 in regulating c-kit mediated Nf1^{+/-} mast cell function .........165

Pak1 and plexiform neurofibroma formation .................................................168

The role of Pak1 in PDGF-BB and TGF-β mediated signaling in fibroblasts.................................................................173

Conclusions and future directions.................................................................176

REFERENCES.......................................................................................................179

CURRICULUM VITAE
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>β</td>
<td>Beta</td>
</tr>
<tr>
<td>BMMC</td>
<td>Bone Marrow Derived Mast Cell</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>CFU-Mast</td>
<td>Colony forming unit, mast cell</td>
</tr>
<tr>
<td>DAPI</td>
<td>4',6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNP</td>
<td>Dinitrophenol</td>
</tr>
<tr>
<td>DRG</td>
<td>Dorsal root ganglion</td>
</tr>
<tr>
<td>ECL</td>
<td>Enhanced chemiluminescence</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene diamine tetraacetic acid</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular regulated kinase</td>
</tr>
<tr>
<td>F-actin</td>
<td>Filamentous actin</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal bovine serum</td>
</tr>
<tr>
<td>FceRI</td>
<td>High affinity IgE receptor</td>
</tr>
<tr>
<td>FGF</td>
<td>Fibroblast growth factor</td>
</tr>
<tr>
<td>FITC</td>
<td>Flouroscein isothiocyanate</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence activated cell sorting</td>
</tr>
<tr>
<td>GRD</td>
<td>GAP related domain</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Granulocyte-macrophage colony stimulating factor</td>
</tr>
<tr>
<td>GAP</td>
<td>GTPase activating protein</td>
</tr>
<tr>
<td>GDP</td>
<td>Guanine diphosphate</td>
</tr>
<tr>
<td>GEF</td>
<td>Guanine nucleotide exchange factor</td>
</tr>
<tr>
<td>GRD</td>
<td>GAP-related domain</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanine triphosphate</td>
</tr>
<tr>
<td>H&amp;E</td>
<td>Hematoxylin and eosin</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</td>
</tr>
<tr>
<td>HSA</td>
<td>Human serum albumin</td>
</tr>
<tr>
<td>IgE-DNP</td>
<td>Immunoglobulin E-dinitrophenyl</td>
</tr>
<tr>
<td>IL-3</td>
<td>Interleukin-3</td>
</tr>
<tr>
<td>IPF</td>
<td>Idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>IS</td>
<td>Inhibitory switch domain</td>
</tr>
<tr>
<td>JMML</td>
<td>Juvenile myelomonocytic leukemia</td>
</tr>
<tr>
<td>K-ras</td>
<td>Kirsten-ras</td>
</tr>
<tr>
<td>KO</td>
<td>Knockout</td>
</tr>
<tr>
<td>LDMNC</td>
<td>Low density mononuclear cells</td>
</tr>
<tr>
<td>LOH</td>
<td>Loss of heterozygosity</td>
</tr>
<tr>
<td>mAB</td>
<td>Monoclonal antibody</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen activated protein kinase</td>
</tr>
<tr>
<td>M-CSF</td>
<td>Macrophage-colony stimulating factor</td>
</tr>
<tr>
<td>MEK</td>
<td>MAPK/ERK Kinase</td>
</tr>
<tr>
<td>MPD</td>
<td>Myeloproliferative disorder</td>
</tr>
<tr>
<td>MNST</td>
<td>Malignant peripheral nerve sheath tumor</td>
</tr>
<tr>
<td>NAG</td>
<td>N-acetylglucosamine</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>NGF</td>
<td>Nerve growth factor</td>
</tr>
<tr>
<td>N-ras</td>
<td>Neuroblastoma-ras</td>
</tr>
<tr>
<td>NF1</td>
<td>Neurofibromatosis type 1</td>
</tr>
<tr>
<td>Nf1</td>
<td>Locus that encodes neurofibromin</td>
</tr>
<tr>
<td>PDGF-BB</td>
<td>Platelet derived growth factor-BB isoform</td>
</tr>
<tr>
<td>PAK</td>
<td>p21 activated kinase</td>
</tr>
<tr>
<td>PBD</td>
<td>p21 binding domain</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PE</td>
<td>Phycoerythrin</td>
</tr>
<tr>
<td>PI</td>
<td>Propidium iodide</td>
</tr>
<tr>
<td>PI3-K</td>
<td>Phosphatidylinositol triphosphate kinase</td>
</tr>
<tr>
<td>PMSF</td>
<td>Phenylmethanesulphonylfluoride</td>
</tr>
<tr>
<td>Ras</td>
<td>Rat sarcoma viral gene</td>
</tr>
<tr>
<td>RPMI</td>
<td>Roswell Park Memorial Institute</td>
</tr>
<tr>
<td>SCF</td>
<td>Stem cell factor</td>
</tr>
<tr>
<td>SH3</td>
<td>Src homology 3 domain</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming growth factor beta</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>WT</td>
<td>Wild type</td>
</tr>
</tbody>
</table>
INTRODUCTION

In 1882, Fredrich von Recklinghausen reported on a 47-year-old male with “innumerable tumors” in the outer skin layer. In this report, he remarked that these tumors were outgrowths of the “externally palpable peripheral nerve trunks”, and in doing so, described the characteristic lesion of the genetic cancer syndrome neurofibromatosis type 1 (NF1) \(^1\). Although reports of probable neurofibromatosis cases date back to the sixteenth century, and despite an initial review of the disease by Robert W. Smith in 1849 \(^2\); it was von Recklinghausen’s seminal observation that the tumors afflicting the skin of patients with this disease are derived from neural tissue that instigated significant clinical interest and linked his name to this disease. Today, more than 250,000 people in the United States, Europe and Japan alone are living with NF1; greater than the number of cystic fibrosis, hereditary muscular dystrophy, Huntington’s disease, and Tay-Sach’s disease patients combined.

Disease manifestations of Neurofibromatosis type 1

NF1 is the most common autosomal dominant genetic disease in humans, with an overall incidence of about 1 in 3500 \(^3\). Together with Neurofibromatosis type 2, Von-Hipple Lindau syndrome, tuberous sclerosis, and Sturge-Weber syndrome, NF1 is historically classified as a phakomatosis (neurocutaneous syndrome), due to the presence of both dermatologic and neurologic sequelae. Individuals affected with NF1 have a propensity to develop an array of non-malignant and malignant clinical complications \(^4\).
Skeletal abnormalities, café-au-lait macules, learning disabilities, and other non-malignant complications of NF1 have significant morbidity for affected patients. In addition, children with NF1 are at an increased risk to develop myeloid disorders, especially juvenile myelomonocytic leukemia (JMML) after NF1 loss of heterozygosity in hematopoietic stem and progenitor cells.\textsuperscript{5,6}

While the development of other neoplasms such as malignant peripheral nerve sheath tumors (MPNSTs), pheochromocytomas and optic gliomas are also well described in NF1 patients; the most commonly found NF1 related tumor is the neurofibroma (>95% of all patients).\textsuperscript{7} These are complex tumors of the central and peripheral nervous system characterized by aggregations of Schwann cells, fibroblasts, and large deposits of extracellular matrix.\textsuperscript{4} Additionally, these lesions are highly vascular with increased concentrations of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).\textsuperscript{8} Furthermore, neurofibromas have a >50 fold higher concentration of mast cells compared to adjacent non-affected areas of skin.\textsuperscript{9}

Neurofibromas can be classified into two basic groups: dermal/subcutaneous or plexiform.\textsuperscript{10} Dermal/subcutaneous neurofibromas are associated with morbidities such as pain, cosmetic problems, and pruritus (that is unresponsive to antihistamine therapy)\textsuperscript{11}. The number of dermal/subcutaneous neurofibromas varies (from <20 to >2000 per individual) from patient to patient as well as between families.\textsuperscript{12,13} Dermal/subcutaneous neurofibromas often appear during the onset of puberty and are known to increase in number and size with age and/or pregnancy\textsuperscript{14}. However, plexiform neurofibromas, which affect 15-40% of NF1 patients, are generally congenital.\textsuperscript{15} These tumors have significant impact in the quality of life of NF1 patients, and plexiform neurofibromas
have the potential to inflict severe morbidity upon NF1 patients, including severe
disfigurement, life-threatening organ dysfunction, and premature death. While
dermal/subcutaneous neurofibromas are usually benign, plexiform neurofibromas are
capable of malignant transformation to MPNSTs. Plexiform neurofibromas carry up to a
10% lifetime risk of malignant transformation, usually accompanied by widespread
metastasis.

At present, therapies for neurofibromas are lacking at best. For
dermal/subcutaneous neurofibromas surgery is the only treatment option, and this is often
impractical or impossible due to the sheer number or complexity of the tumors.
Furthermore, surgical resection of dermal/subcutaneous neurofibromas is often followed
by regrowth of the tumor and/or hypertrophic scarring. Plexiform neurofibromas, due
to their location, mass, and diffuse morphology, create significant challenges for effective
treatment. Many plexiform neurofibromas are not candidates for surgical resection due
to the risk of hemorrhage owing to the highly vascular nature of these tumors (especially
facial plexiforms) as well as encroachment into neighboring structures. Radiotherapy of
benign plexiform neurofibromas is contraindicated due to the risk of instigating
malignant change. Furthermore, no effective medical therapies for neurofibromas
exist. Considering the significant clinical complications caused by neurofibromas in
patients, the need to identify molecular targets for pharmacologic therapies is pressing.
Genetic basis of neurofibromatosis type 1

Work using linkage analysis identified the gene responsible for NF1 to reside on chromosome 17 \(^{18}\). Positional cloning led to the discovery of the \(NF1\) locus at 17q11.2 \(^{19-21}\). The \(NF1\) locus is composed of 60 exons that span over 300kb of genomic DNA and encodes a protein, neurofibromin, which contains 2818 amino acids \(^{22-24}\). Neurofibromin is ubiquitously expressed in all tissues; however, neurons, Schwann cells, astrocytes, oligodendrocytes, and leukocytes are noted for their exceptionally high expression of \(NF1\) \(^{19,25}\). Approximately 50\% of NF1 diagnoses are the result of new mutations \(^{26}\); therefore it is not surprising that a variety of \(NF1\) mutations have been described, including missense replacements and truncations along the length of the entire gene \(^{27}\). It is interesting to note that to date, no correlation between specific mutations and clinical presentation or severity has been reported \(^{27}\).

Murine models of Neurofibromatosis type 1

Initial attempts to model neurofibromatosis in mice used homologous recombination techniques to target \(Nf1\), the murine homolog of \(NF1\), for disruption \(^{28}\). Attempts to generate \(Nf1^{+/-}\) mice were not successful, as these embryos died between days 12 and 14 post-coitus due abnormalities of cardiac development, specifically located in the outlet vessels of the right ventricle \(^{28}\). Furthermore, while \(Nf1^{+/-}\) mice were generated without cardiac malformations, a proportion of \(Nf1^{+/-}\) mice (~10\%) did develop a myeloproliferative disorder reminiscent of JMML during the second year of life,
complete with leukemic cells that display loss of heterozygosity at the intact Nf1 allele and in vitro hypersensitivity to GM-CSF, similar to human JMML samples. Importantly, Nf1+/− mice do not develop either dermal/subcutaneous or plexiform neurofibromas. However, since NF1 patients are obligate heterozygotes, these animals have proven useful for studying the basic cellular biology of cells found in and near neurofibromas.

A second generation of murine neurofibromatosis type 1 models was initiated with the development of a conditionally deleted Nf1 mouse, using a Cre-Lox system. By breeding the Nf1fl/fl mice with mice that expressed Cre driven by various lineage selective promoters, adult mice could be generated with specific organ systems that totally lacked neurofibromin. Creating a conditional knockout of Nf1 that caused deletions in Schwann cells (by means of the Krox20 promoter driving Cre expression) yielded interesting results. Although tumor samples from patients have demonstrated that Schwann cells harbor the somatic NF1 mutation, mice that contained Nf1 null Schwann cells (Krox20Cre:Nf1fl/fl) did not develop neurofibromas. However, despite the fact that Krox20Cre:Nf1fl/fl mice are functionally wild type, Krox20Cre:Nf1flox/flox mice that were backcrossed with Nf1+/− mice to generate one conditionally deleted allele and one traditionally disrupted allele (Krox20Cre:Nf1flox/) developed multiple neurofibromas.

These experiments demonstrated that nullizygosity of Nf1 in tumorigenic Schwann cells is necessary, but not sufficient for plexiform neurofibroma formation. Critically, haploinsufficiency of Nf1 in at least a subset of lineages within the tumor microenvironment is required to promote neurofibroma development. The results generated from the Krox20Cre NF1 murine model have laid a foundation for the
development of rationally designed therapeutics that target the cells of the microenvironment rather than the tumorigenic cells alone.

**Role of mast cells in neurofibroma formation**

Virchow first hypothesized that cancer was the result of an overactive inflammatory response in 1863; indeed, recent studies in multiple murine models have supported this hypothesis and implicated that inflammatory cells are essential for the progression to malignancy. Chronic inflammation is well known to contribute directly to the formation of breast, hepatic, dermal, ovarian, prostate, and many other carcinomas. Patients with chronic inflammatory diseases such as Crohn’s disease and ulcerative colitis have increased risks for developing colorectal carcinoma. Further evidence underscoring the importance of inflammation on colon cancer development were studies demonstrating patients who were treated long term with non steroidal anti inflammatory drugs (NSAIDs) had nearly a 50% reduction in their overall risk of developing large bowel adenocarcinoma.

Besides mediating innate immune responses and allergic hypersensitivity, there is an emerging understanding that inflammatory mast cells in the tumor microenvironment have relevance in the promotion of neoplastic development as well. Described relationships between mast cells and tumors date back over 100 years; Mast cells in particular are critical for the transformation to malignancy in a squamous epithelial cancer murine model, by releasing matrix metalloproteinases such as tryptase and activating progelatinase B to activate the angiogenic switch. Since mast cells are the
predominant inflammatory cell found in the neurofibroma microenvironment and are found at such high density at these sites 9, we have been particularly interested in understanding the potential role these cells play in neurofibroma pathophysiology.

One notable observation drawn from the Krox20Cre;Nf1\textsuperscript{floxed} mouse model is the appearance of mast cells in peripheral nerves well in advance of tumor development 30. Our laboratory has generated data identifying potential mechanisms that regulate the unique association of mast cells with neurofibromas, centered on the c-Kit/stem cell factor (SCF) signaling axis. SCF, a glycoprotein also known as Steel factor, mast cell growth factor or Kit ligand, is the ligand of the receptor tyrosine kinase (RTK) c-kit 42,43. SCF exists in both soluble and membrane-bound forms 44. SCF is a cytokine that induces pleiotropic effects; resulting in the growth and development of hematopoietic stem cells 45, germ cells 46, and melanocytes 47. Importantly, SCF is a potent mitogenic factor for mast cells 48-50. SCF also stimulates mast cell chemotaxis 51,52 and survival 53,54. Upon stimulation with SCF or cross-linking of IgE molecules on the cell surface, mast cells release numerous inflammatory byproducts 55,56. These include VEGF, which stimulates angiogenesis and Schwann cell proliferation 57, transforming growth factor beta (TGF-β) 58, which is a known growth factor for fibroblasts, as well as many reactive oxygen species and proteases. Therefore, mast cells have the ability to stimulate the growth of cells that compose the neurofibroma as well as remodel the extracellular matrix.

We have demonstrated that Nf1 haploinsufficient mast cells have increased proliferation, survival, migration, and degranulation \textit{in vitro} and \textit{in vivo} 59-61. These findings identify that loss of one copy of Nf1 has functional consequences in mast cells.
We have shown that \(Nf1^{+/-}\) mast cells preferentially migrate toward SCF released from \(Nf1^{-/-}\) Schwann cells compared to wild type mast cells \(^{62}\). This Schwann cell/mast cell interaction resulting from the hypersecretion of SCF is thought to be an inciting factor in the early development of neurofibromas \(^{63}\).

Studies by Dr. Feng-Chun Yang have revealed the importance of contributions from bone marrow derived cells to neurofibroma development \textit{in vivo}. \(Nf1^{+/-}\) bone marrow was transplanted into \(Krox20\text{Cre};Nf1^{\text{flax/flax}}\) mice (which normally do not develop tumors). By one year post-transplant, 100\% of the \(Krox20\text{Cre};Nf1^{\text{flax/flax}}\) mice reconstituted with \(Nf1^{+/-}\) marrow had neurofibromas \(^{64}\). As a complementary experiment, wild type marrow was transferred into \(Krox20\text{Cre};Nf1^{\text{flax/flax}}\) mice (which spontaneously develop tumors). Interestingly, by one year post transplant, these \(Krox20\text{Cre};Nf1^{\text{flax/flax}}\) mice did not generate neurofibromas \(^{64}\). These experiments show that \(Nf1\) haploinsufficiency in the hematopoietic portion of the tumor microenvironment is required to induce Schwann cells into forming neurofibromas.

Additional experiments utilized \(Krox20\text{Cre};Nf1^{\text{flax/flax}}\) mice transplanted with \(Nf1^{+/-}; W^{d1} W^{d1}\) marrow. The \(W^{d1}\) mutation in the c-kit receptor kinase domain leads to mice with a mottled coat color, normal bone marrow cellularity, mild but persistent anemia, and markedly decreased numbers of mast cells and their progenitors \(^{65}\). \(Krox20\text{Cre};Nf1^{\text{flax/flax}}\) mice that were recipients of \(Nf1^{+/-}; W^{d1} W^{d1}\) marrow did not develop plexiform neurofibromas \(^{64}\), implying that the identity of the active component of the tumor-promoting hematopoietic compartment to be a c-Kit dependent cell type, such as mast cells. Given the results from \textit{in vitro} studies on mast cell activity and our data using
the *Krox20Cre* conditional knockout of *Nf1*, we hypothesize that haploinsufficiency at *Nf1* in mast cells specifically is required for the evolution to neoplasia *in vivo*.

**Fibroblasts contribute to neurofibroma pathology**

Fibrosis often develops in chronic inflammatory conditions that involve large-scale mast cell activation. In pathologically fibrotic conditions such as scleroderma, post-operative peritoneal adhesions, and radiation induced lung fibrosis, high densities of mast cells are observed. Mast cells can provide growth factors that stimulate this fibroblast growth and invasion, such as TGF-β and PDGF. Indeed, fibroblasts that are disrupted at *Nf1* have a reduced capability to form perineurial sheaths around Schwann cells, allowing increased access for mast cells and serum growth factors to Schwann cells.

Furthermore, we have recently demonstrated that *Nf1*+/- mast cells secrete increased amounts of TGF-β, and that this leads to Ras dependent gains of function in proliferation, migration, and ECM secretion by *Nf1*+/- fibroblasts. This data provides a potential mechanism for the profound fibrosis seen histologically in neurofibroma...
samples and again implicates the mast cell as an inducer, via paracrine factors, of cellular events important for neurofibroma formation.

Ras hyperactivation: the molecular basis of NF1

As a tumor suppressor, neurofibromin functions as a member of a molecular switchboard involved in transducing extracellular signals to the nucleus via Ras\(^3\). Neurofibromin acts as an important negative regulator of this signaling network by acting as a GTPase activating protein (GAP) via its binding to active Ras and increasing GTP hydrolysis\(^72\). In hematopoietic cells, p120 GAP is also expressed, although the gene encoding this protein is not associated with cancer development\(^73\). The Ras-GAP related domain (GRD) responsible for GTPase inactivation is located between amino acids 1125-1537 in NF1\(^20\). NF1 GRD is highly homologous with p120 GAP catalytic domain\(^72\); however, reconstitution of Nf1 deficient cells with Nf1 GRD, but not p120 GRD, is sufficient to correct gain-in-function phenotypes, both \textit{in vitro} and \textit{in vivo}\(^{62,74,75}\). Although neurofibromin has been described to regulate cAMP levels\(^76\) and associate with microtubules\(^77\), to date, Ras-GRD is the only domain within neurofibromin with an associated biological function that has an impact on disease\(^10\).

Ras coordinates the growth, differentiation, and survival of many cell types and its activation status is tightly regulated\(^78\). Upon ligand binding, numerous growth factor receptors (including c-Kit) recruit Ras to the plasma membrane and initiate the formation of an activation complex that includes the Grb2 adapter and guanine nucleotide exchange factor Sos, which loads GTP onto Ras. Signal transduction from the Ras network
proceeds until GAP proteins are able to bind Ras and facilitate the hydrolysis of GTP to GDP. Therefore loss or inactivation of \textit{Nf1} leads to a shift towards increased Ras-GTP vis-à-vis Ras-GDP, leading to hyperactivation of downstream signaling molecules \textsuperscript{79}. Hyperactivation of Ras at the molecular level is believed to be responsible for NF1 related pathologies ranging from JMML \textsuperscript{80}, pilocytic astrocytomas \textsuperscript{81}, optic glioma \textsuperscript{82}, learning disabilities \textsuperscript{83}, and neurofibromas \textsuperscript{84}.

\textbf{Signaling pathways disrupted in the absence of neurofibromin}

Ras activation by in response to growth factor stimulation leads to the recruitment and activity of Raf-1 serine/threonine kinase \textsuperscript{85}. Raf-1, in turn activates the MAPKK Mek1/2 \textsuperscript{86} and subsequently p42/p44 MAPK (Erks) \textsuperscript{87,88}. This classical Ras/Raf/Mek/Erk cascade is well described as essential to numerous cells type for the proliferation and survival signals sent by growth factors such as interleukin-3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF), and many others \textsuperscript{89-91}. Many groups have found hyperactivation of the Ras/Raf/Mek/Erk pathway following growth factor stimulation in the context of neurofibromin deficiency, particularly in cellular lineages relevant to neurofibromas, including: Schwann cells \textsuperscript{92}, fibroblasts \textsuperscript{71}, endothelial cells \textsuperscript{93}, vascular smooth muscle cells \textsuperscript{94}, and mast cells \textsuperscript{59}.

Additionally, Ras has been demonstrated to bind to the p110 catalytic subunit of Class I phosphatidylinositol 3-kinases (PI3-K), leading to increased lipid kinase activity \textsuperscript{95}. Similar to Ras, PI3-K itself transduces signals through a number of networks to regulate multiple cellular functions \textsuperscript{95}. Some downstream effectors of PI3-K have been
shown to be hyperactivated in neurofibroma-associated cells without neurofibromin; including Akt $^{60,96}$, mTOR $^{97}$, p70S6 kinase $^{97}$, and the small GTPase Rac1/2 $^{60}$.

While the critical contribution of the Ras/Raf/Mek/Erk pathway to NF1 associated phenotypes is well known, the prolonged activation of this pathway is dependent on other signals, including PI3-K $^{98}$. Work from our laboratory has established that pharmacologic inhibition or genetic disruption of PI3-K in Nf1 +/- mast cells will reduce the SCF mediated hyperactivation of Raf-1, Mek1/2 and Erk1/2 kinase activity in vitro $^{60}$, implying the existence of cross talk between the PI3-K and MAPK pathways. Further efforts showed that genetic loss of Rac2, and important downstream target of PI3-K will correct the hyperactivation of Erk, as well as the gains in proliferation in Nf1 +/- mast cells $^{60}$. However, identification of the mediators downstream of Rac that are responsible for the inter-pathway signaling in Nf1 +/- mast cell activity is incomplete. Elucidation of the specific molecules involved in the hyperactive gain-in-function phenotypes associated with Nf1 haploinsufficiency is critical for understanding the biochemical mechanisms underlying tumor pathophysiology in NF1.

p21 activated kinases: downstream effectors of Rho GTPases

The Ras related-Rho family of GTPases (including Rac, Rho, cdc42, among others) are molecular switches that regulate a wide variety of cellular activities that are important in normal as well as pathological states $^{99}$. The Rho GTPase family has roles in cellular functions as diverse as cytoskeletal activation and regulation, vesicle transport, gene expression, cell cycle transitioning, and oxidant generation $^{100}$. Considerable effort
has been put forth in identifying the signaling networks downstream of these GTPases and their related functions. The first kinase proteins known to be regulated by the Rho family of GTPases were identified in 1994 in a gel overlay assay for Rac1 binding partners, and were termed p21 activated kinases, or Paks. The binding partners found at 68, 65, and 62 kd were later termed Pak1 (or α-Pak), Pak3 (or β-Pak), and Pak2 (or γ-Pak), respectively. Pak1 was found to share 77% identity with Pak2 and 81% identity with Pak3. Pak proteins interacted only with active (GTP), not inactive (GDP) bound Rac or cdc42. Furthermore, the intrinsic phosphotransferase activity of Paks on myelin basic protein was dramatically increased after interacting with GTP bound Rac or cdc42.

Sequence analysis of the Pak proteins showed high homology with the yeast Ste20 serine/threonine kinase. Phylogenetic investigations have revealed that all eukaryotic kinomes contain multiple members of the Ste20 family. Paks and Ste20 have a highly conserved catalytic domain located near the C-terminus (amino acid residues (aa) 255–529 in PAK 1). Outside of this catalytic domain, Paks and Ste20 diverge in sequence, save for a short regulatory region close to the N-terminus. This regulatory region, called the p21 binding domain or PBD (aa 67-113 in Pak1), is very highly conserved among all Ste20 proteins and allows for binding with activated Rac or cdc42. Overlapping with, but not congruent to, the PBD is an autoinhibitory segment known as the inhibitory switch (aa 83-149 in Pak1) that regulates basal kinase activity. Other sequence commonalities between Paks1-3 include two N-terminal canonical PXXP SH3-binding domains, the first has been shown to interact with the adapter protein Nck, the second binds to Grb2; as well as a non-classical PXP SH3-binding domain,
known to interact with PIX (also known as Rac/cdc42 GEF6) 110. Furthermore, Pak1 contains two additional PXXP SH3-binding domains in its N-terminal region that are not found in Pak2.

Crystal structure of Pak1 revealed it exists as an inactivated homodimer in vivo, arranged in a trans-inhibited conformation: the N-terminal autoinhibitory segment of one of the dimer partners binds and inactivates the C-terminal catalytic domain of the other 111. Binding of GTP-bound Rac to the PBD of one of the dimer partners disrupts dimerization, causing conformational changes that destabilize the inhibitory switch and disassociate it from its partner’s catalytic domain 101. Once freed from the dimerized state, the kinase domain is capable for catalytic function 107. However, full catalytic efficiency and sustained alleviation from reforming autoinhibitory dimers requires phosphorylation in the activation loop of the catalytic domain (Thr423 in Pak1) 112-114. In addition to phosphorylation at Thr423, Pak1 kinase activity is also upregulated by phosphorylation at Ser144, which is located in the inhibitory switch domain 115. Both of these residues are known autophosphorylation sites; however, maximal Pak1 kinase activity is dependent upon PDK1 phosphorylation of Thr423 after Rac/cdc42 binding 113,116.

Although Pak proteins are primarily thought of and initially discovered as downstream effectors of Rac and cdc42, GTPase independent activation has also been described. The SH3-binding domains in the N-terminal region allow for membrane recruitment by Nck and Grb2, which leads to induction of Pak kinase activity 117-119. Also, Paks are autophosphorylated and activated following certain protease treatments 120. For example, Pak2, but not Pak1, is constitutively activated following
cleavage by caspase 3 at Asp212 during apoptosis. Lipids such as sphingosine and sphingosine derived lipids, gangliosides, and phosphatidic acids all are known to activate Pak1 independent of GTPase binding. The understanding of the physiologic importance of lipid activation relative to GTPase activation of Pak1 is incomplete at best.

Despite having high affinity for myelin basic protein and histone H4 in in vitro kinase assays, it is unlikely that Pak1 phosphorylates these proteins in physiologic systems. Biochemical studies have indicated that Pak1 is a “basic directed” kinase, with a (K/R)RXS target sequence for phosphorylation. This is a similar phosphorylation sequence to proteins such as PKA and PKC; however, an acidic residue at the -1 position is well tolerated by Pak but not by PKA and PKC. In addition, Pak1 cannot tolerate proline residues at -1 or +1 positions, which are required critical for substrate phosphorylation by proline directed kinases such as MAPKs and cdc2, indicating that Pak1 and proline-directed kinases do not share phosphorylation targets.
Figure 1

A

Nck  Grb2  Cdc42  Rac1  PIX

N  IS domain  Catalytic domain
(Inhibitory Switch)

B

Inactive conformation  Active conformation

Figure 1- Structure of Pak1. A) Schematic representation of relevant domains in primary structure of Pak1. The PXXP SH3-binding sites of Pak1 for the adaptors Nck and Grb2, the PXP SH3-binding site for the exchange factor PIX, and the PBD for the GTPases Cdc42 and Rac1 are shown. B) Diagram of conformational changes induced upon activation by GTPases. The inactive state is a trans-inhibited dimer. The IS domain overlaps portions of the PBD, regulates the dimerization of Pak1 and inhibits the kinase activity of the other member of the Pak1 homodimer. GTPase binding to the PBD leads to conformational changes of the IS domain, releasing the Pak1 homodimer. The active state is a monomer whose open conformation is stabilized by auto-phosphorylation. This figure was first published in its original form by M.C. Parrini, et al. in Biochem. Soc. Trans. 33, 646-648 (2005).
Pak is a multifunctional signal transducer

Pak1 is well described as a modulator of cytoskeletal dynamics. Immunofluorescence analysis of cells stimulated with agents such as PDGF, insulin, and transformation by v-src revealed subcellular localization of Pak1 into cortical actin structures\(^{124}\). This interaction with the cytoskeleton helps regulate motility, as expression of dominant negative Pak1 lead to decreased migration of NIH-3T3 cells, with associated loss of organized actin structures\(^{125}\). Conversely, overexpression of constitutively active Pak1 lead to increases in both motility as well as large actin structures at the leading edge\(^{125}\). Pak1 has a number of downstream targets that regulate actin organization and polymerization, including filamin A, which leads to crosslinking of filamentous actin into orthogonal networks at the membrane\(^{126}\); and LIM kinase, which inactivates the F-actin destabilizing protein coflin, leading to aggregation of F-actin fibers\(^{127}\). Pak can also regulate microtubule dynamics through its inactivation of the microtubule destabilize stathmin\(^{128}\). One working model of Pak and its critical role in regulating cell motility describes Pak1 being activated by Rac and cdc42 near the leading edge of the cell after chemotactic stimulation, leading to stabilization of actin structures after activating Filamin A and inhibiting coflin (via LIM kinase) and maintenance of growing microtubule structures by inhibition of stathmin\(^{101}\).

In addition to regulating the cytoskeleton, Pak has an important role in regulating activation of MAPK signaling pathways. This role was initially suggested from the fact that Ste20 is known to act as a MEKK (MAPK/Erk kinase kinase) in yeast pheromone signaling\(^{106}\). Pak1 directly activates Raf-1, by phosphorylating serine residue 338\(^{129}\).
Phosphorylation of Ser338 is critical for full activation of Raf-1 kinase activity \(^{130}\). In addition, Pak1 also directly activates MEK1, phosphorylating serine 298 \(^{131}\). Serine 298 is important for “priming” MEK1 for activation by increasing Raf-1 kinase activity toward Ser217/221 on MEK, leading to increased Mek kinase activation \(^{132}\). Furthermore, transfection of siRNA to Pak1 greatly reduced Erk activation by PDGF in NIH-3T3 cells, associated with congruent decreases in Raf and Mek activity \(^{133}\). The phosphorylation of Pak1 targets on Raf-1 (Ser338) and Mek1 (Ser298) can increase efficiency of Erk activation by facilitating protein-protein interactions and result in increased responses to low-level stimuli \(^{134}\).

Besides activating the Erk MAPK, overexpressed Pak1 has also been reported to activate p38 MAPKs \(^{135,136}\). Overexpression of constitutively active Pak1 increases p38 kinase activity following phosphorylation at Thr180 \(^{136}\). p38 activity following growth factor stimulation is linked to the migration of numerous cell types; overexpression of dominant negative Pak1 impedes p38 dependent migration in smooth muscle cells \(^{137}\) and macrophages \(^{138}\). Unlike the well described interactions between Pak1 and the Raf/Mek/Erk pathway, the manner in which Pak1 effects p38 is incompletely understood. p38 is not a direct target of Pak1 kinase activity, and the exact mechanism of how Pak1 leads to increased p38 activity is unclear. Even less understood is the relationship between Pak1 and JNK. Overexpression of Pak1 has produced reports that indicate both enhanced \(^{135,139,140}\) as well as impaired \(^{141,142}\) JNK activity. Pak/JNK interactions may be cell type specific, and as with p38, the nature of these inchoate interactions requires further examination \(^{101}\).
In multiple cellular systems, Pak1 has been reported to be a member of an anti-apoptotic signaling network via its interactions with Bad\textsuperscript{143-146}. Bad is a death promoting Bcl-2 family member that binds to Bcl-2 and Bcl-xL, preventing their anti-apoptotic activities\textsuperscript{146}. However, after phosphorylation, Bad is unable to associate with Bcl-2 or Bcl-xL, and instead is sequestered by the 14-3-3 cytosolic adapter protein. Pak1 phosphorylates Bad at Ser112 and Ser136 \textit{in vitro} and \textit{in vivo}, leading to decreased association of Bad with Bcl-2 and Bcl-xL and corresponding decreases in apoptosis following stimulation with survival signals\textsuperscript{143}.

\subsection*{Cancer and Pak1}

In recent years, Pak1 activity has been linked to the development of an extremely wide variety of human cancers, including: breast\textsuperscript{145,147-149}, melanoma\textsuperscript{150}, glioblastoma\textsuperscript{151}, bladder\textsuperscript{152}, kidney\textsuperscript{153}, ovarian\textsuperscript{154}, liver\textsuperscript{155}, colorectal\textsuperscript{156}, and pancreatic\textsuperscript{157}. The role of Pak1 in carcinomas of the breast is very well documented. Initial reports described PI3-K/Pak1 dependent reorganization of the actin cytoskeleton following heregulin stimulation, leading to increased migration of breast cancer cells\textsuperscript{158}. More recent reports have focused on overexpression of Pak1 in breast cancer cells, particularly in the nucleus, resulting in increased phosphorylation of the estrogen-receptor alpha and subsequent progressive tamoxifen resistance\textsuperscript{159}.

In addition, Pak1 activity has been linked to oncogenic processes in cell types relevant to neurofibromas. Pak1 initially drew attention with regards to NF1 due to the fact that Pak1 can induce many cellular functions similar to those caused by activated
Ras. In Rat-1 fibroblasts, kinase dead Pak1 reduced oncogenic transformation mediated by overexpression of K-Ras by over 90% in soft-agar foci assays. This result was linked to the decreased Erk activation found in the Rat-1 cells that co-expressed K-Ras and kinase dead Pak1. In a similar manner, expression of dominant negative Pak1 in rat Schwann cell lines prevented Ras-mediated transformation. Using a NF1−/− Schwann cell line taken from a NF1 patient, mouse xenograft experiments revealed that in vivo tumorigenicity could be greatly reduced by transfecting the NF1 null Schwann cells with kinase dead Pak1 prior to implantation. Other groups using FK228, an inhibitor of the histone deacetylase complex that reduces Pak1 kinase activity, have shown that treatment of mice with FK228 causes the complete regression of xenografts resulting from MPNST cells derived from NF1 patients. Importantly, Nfi+/− mast cells that have been stimulated with SCF have increased Pak1 kinase activity. Given this finding and the critical role ascribed to Rac in regulating Nfi haploinsufficient gains-in-function, Pak1 is an appealing candidate gene for modulating the hyperactive MAPK signaling in cells of the tumor microenvironment that allows neurofibroma progression.

Thesis overview

Identification of the specific mediators downstream of hyperactive Ras is critical for understanding the biochemical mechanisms underlying the abnormal cell phenotypes that contribute to the pathophysiology of neurofibromas in NF1. Studies described here examine the role of Pak1 in regulating aberrant Ras signaling in cells that have disruptions in Nfi. The aims of this work are threefold, first to evaluate the role of Pak1
as an effector of SCF mediated gain-in-function phenotypes associated with Nf1 haploinsufficiency in mast cells \textit{in vitro} and \textit{in vivo}. Second, we use a conditional \textit{Nf1} knockout animal disease model to determine the significance of Pak1 disruption in the development of \textit{Nf1} deficient neoplasia such as a plexiform neurofibroma. And third, we examine if Pak1 loss has functional consequences in PDGF and TGF-\(\beta\) mediated signaling events and cellular functions in fibroblasts. We expect that these studies will provide unique insights into the pathophysiology of NF1 and highlight Pak1 as a possible drug target for the treatment of the disease.
Figure 2

SCF → c-Kit

Neurofibromin

Ras [GDP] → Ras [GTP]

MAPKs

Proliferation
Migration
Degranulation

PI-3 Kinase

Rac1/2

?
Figure 2- Schematic representation of signaling events associated with *Nf1* haploinsufficiency. Ras is activated by the binding of SCF to its receptor c-Kit, which activates a number of GEFs that catalyze the conversion of inactive Ras-GDP to active Ras-GTP. Disruptions at *Nf1* prevent the normal conversion of active Ras back to its inactive state, leading to its hyperactivation. Hyperactive Ras in turn recruits and activates the MAPK effector pathway that ultimately increase many cellular functions, including proliferation, migration, and degranulation. These gains-in-function and increases in MAPK signaling are dependent upon Ras activation of PI3-K/Rac. The signaling events downstream of Rac that lead to MAPK hyperactivation are incompletely understood.
MATERIALS AND METHODS

ANIMALS

Nf1+/− mice were obtained from Tyler Jacks at the Massachusetts Institute of Technology (Cambridge, MA) in a C57BL/6.129 background and backcrossed for 13 generations into the C57BL/6J strain. Pak1 −/− mice were generated in Dr. Jonathan Chernoff’s Laboratory (Temple University) and are backcrossed six generations to be on a C57BL/6J strain. These studies were conducted with a protocol approved by the Indiana University Laboratory Animal Research Center. The Nf1 allele was genotyped as described previously. The Pak1 allele was genotyped by PCR using the following primers: Pak1 Forward = GCCCTTCACAGGAGCTTAATGA, Pak1 Reverse: GAAAGGACTGAATCTAATAGCA, neoReverse: CATTTCACGTCTCTAATAGCA set up in two separate reactions (one for WT and one for KO band) PCR program Pak1: 94 2 min, 94 20s (92 for KO reaction), 52 (58 for KO reaction) 20s X 35 cycles, 71 2min, 71 7 min, 4 48 hr. WT Reaction, yields a 240 bp band; KO reaction, yields a 360 bp band. Multiple F0 founders were used to generate the four Nf1 and Pak1 genotypes used in these experiments as outlined. F0: Nf1+/−; Pak1+/+ x Nf1+/+; Pak1−/−. F1: Nf1+/−; Pak1+/− x Nf1+/+; Pak1+/−. F2: Nf1+/−; Pak1−/−, Nf1+/+; Pak1−/−, Nf1+/−; Pak1+/+, Nf1 +/+; Pak1+/−.

BONE MARROW MAST CELL CULTURE

BMMCs were cultured in RPMI (Gibco BRL) supplemented with 10% fetal calf serum (HiClone), 1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2%
penicillin/streptomycin (BioWhittaker) and 5 ng/mL IL-3 (Peprotech). Cells were cultured in a 37°C, 5% CO₂, humidified incubator. All proliferation, migration, and biochemical assays utilized BMMCs that had been in culture between four to eight weeks. All experiments were conducted using at least three independent lines from each genotype.

**MAST CELL PROGENITOR ASSAY**

Using an established methylcellulose culture based method, we determined the *in vitro* mast cell colony forming ability of Pak1-/− and Nf1+/-;Pak1-/− bone marrow. Briefly, whole marrow from both femurs and tibias were collected from animals and pooled. LDMNC were isolated using Histopaque 1119 (Sigma Aldrich) and counted using a hemocytometer. 2x10⁴ cells were then plated in 1mL methylcellulose containing 20% fetal calf serum (HiClone), 1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2% penicillin/streptomycin (BioWhittaker), 2.5ng/mL IL-3 (Peprotech), and 10ng/mL SCF (Peprotech). After 21 days growth in a 37°C, 5% CO₂, humidified incubator, the surviving mast cell colonies were counted and are expressed as number of mast cell colonies per animal. Assays were performed in triplicate.

**MAST CELL MATURATION**

Maturation of cultured bone marrow mast cells was assayed by the expression levels of c-Kit and FcεRI using fluorescence cytometry as described in other reports. 4-week-old mast cell cultures were blocked with unconjugated anti-FcγRII/III (BD Pharmingen) and washed. This was followed by incubation with anti-DNP monoclonal antibody IgE clone SPE-7 (Sigma Chemical Co), anti-mouse CD 117 (c-kit) PE conjugated antibody (BD
Pharmingen), and FITC conjugated anti-mouse IgE (BD Pharmingen) secondary antibody. Cells were then washed to remove unbound antibodies and resuspended in 0.5% BSA PBS Buffer. Aliquots of mast cells were also stained with FITC and PE conjugated rat IgG2b,K isotype antibodies to serve as negative controls. Cells were analyzed by FACS™. Cells that were double positive for both c-kit and FceRI were considered to be mature and suitable for use in in vitro experiments.

MAST CELL IMMUNOBLOTTING

Whole cell protein extracts were obtained from SCF stimulated BMMC in lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA pH 8.0, 1% Triton X-100, 1mM PMSF, 1mM NaF, 1mM Na3VO4, 10% glycerol and Complete protease inhibitor), and equivalent amounts of protein were electrophoresed on 10% SDS-PAGE gels, transferred to nitrocellulose membranes (Amersham Biosciences), and detected by Western blotting using the ECL Plus system (Amersham Biosciences). Antibodies used were Phospho-p44/42 MAPK (Thr202/Tyr204) (197G2) Rabbit mAb (Cell Signaling Technology), p44/42 MAP Kinase Antibody (Cell Signaling Technology) Phospho-MEK1/2 (Ser217/221) Antibody (Cell Signaling Technology), Anti-MEK1, NT (Upstate), Phospho-MEK1/2 (Ser298) Antibody (Biosource International) Anti-phospho-Raf-1 (Ser338) (Upstate), Monoclonal β-actin antibody (clone AC-15) (Sigma-Aldrich).

MAST CELL PROLIFERATION ASSAY

Proliferation assays were performed as described previously 59. Briefly, BMMCs from each genotype were deprived of growth factors for 24 h, and treated with 10μM
Mek1 inhibitor PD98059 (Biosource International), 10µM p38 MAPK inhibitor SB203580 (Biosource International) or DMSO for 2h prior to stimulation. 3 x 10^5 cells were plated in 24-well dishes in 1 ml RPMI containing 10% fetal calf serum, 1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), 2% penicillin/streptomycin (BioWhittaker), and 50 ng/ml SCF (PeproTech) or no growth factors as indicated in a 37°C, 5% CO₂, humidified incubator. After 72 h, cells were counted using a hemocytometer. Cell viability was determined by a trypan blue exclusion assay. Assays were performed in triplicate.

MAST CELL HAPTOTAXIS ASSAY

To evaluate mast cell migration, a transwell haptotaxis assay was used as previously described 164,166. 2.5x10^5 cells were resuspended in 100 µl RPMI with 10µM Mek1 inhibitor PD98095 (Biosource International), 10µM p38 MAPK inhibitor SB203580 (Biosource International) or DMSO for 2h prior to stimulation. These cells were loaded onto transwell filters (8mm pore filter Transwell, 24 well cluster; Costar) that were coated with recombinant fibronectin fragment (Retronectin CH296, Takara), which then were placed in wells containing 600 µl of serum free RPMI supplemented with 25ng/mL SCF. After four hours of incubation at 37°C in 5% CO₂, non-migratory cells on the upper membrane surface were removed with a cotton swab, and migrated cells attached to the bottom surface of the membrane were stained with 0.1% crystal violet in 0.1 M borate, pH 9.0, 2% ethanol for 10 minutes at room temperature. The average number of migrated cells per higher-power field was counted with an inverted microscope using the 20x objective lens. Assays were performed in triplicate.
F-ACTIN QUANTITATION

To evaluate F-actin content, BMMCs were pre treated with inhibitors and stimulated as described above for migration assays. After 30 minutes of incubation at 37°C in 5% CO₂ cells were removed from the upper chamber of the transwell and placed into 3.7% formaldehyde solution for fixation. Fixed cells were treated with 0.01% Triton X-100 (Sigma-Aldrich) in PBS for 5 minutes at 25°C, washed, and then incubated with 160nM Alexa Fluor® 488 Phalloidin (Invitrogen) for 20 minutes at 25°C prior to FACS analysis by fluorescence cytometry. A minimum of 10,000 mast cell events were recorded, and the results are reported as the fold increase in mean channel fluorescence from unstimulated cells. Assays were performed in triplicate.

CONFOCAL MICROSCOPY

To evaluate F-actin organization, BMMCs were pre treated with inhibitors and stimulated as described above for migration assays. After 30 minutes of incubation at 37°C in 5% CO₂ cells were removed from the upper chamber of the transwell and were placed into cytospin chambers for centrifugation onto microscope slides. The slides were placed into 3.7% formaldehyde solution for fixation. Fixed cells were treated with 0.01% Triton X-100 (Sigma-Aldrich in PBS for 5 minutes at 25°C, washed, and then incubated with 160nM Alexa Fluor® 488 Phalloidin (Invitrogen) for 20 minutes at 25°C prior to mounting with DAPI. Cells were then analyzed via confocal microscope with the Zeiss UV LSM-510 system. Quantization of the fluorescent intensity of the confocal image was analyzed using NIH ImageJ software.
MAST CELL DEGRANULATION ASSAY

Measurements of in vitro degranulation of mast cells are proposed using a β-hexosaminidase release assay as previously described\textsuperscript{167,168}. Four to six weeks after initiation of culture, BMMCs were washed and sensitized for 2 hours at 2 x 10^6 cell/ml in 0.5% BSA RPMI 1640 containing 1.5 μg/ml of anti-DNP IgE monoclonal antibody (clone SPE-7, Sigma Chemical Co). Excess antibody was removed and cells were resuspended at 2 x 10^6 cells/ml in Tyrode’s buffer (10 mM HEPES buffer, 130 mM NaCl, 5 mM KCl, 1.4 mM CaCl2, 1mM MgCl2, 5.6 mM glucose, and 0.05% BSA, pH=7.4). Sensitized BMMCs were then stimulated with 30ng/ml dinitrophenyl conjugated to human serum albumin (DNP-HSA) (Sigma Chemical Co.) and 25ng/ml SCF for 15 minutes at 37°C. The cell pellet was solubilized in Tyrode’s buffer, 0.5% Triton X-100. β-hexosaminidase release was measured in both the supernatant and the cell pellet by incubating with 4-Nitrophenyl N-acetyl-beta-D-glucosaminide (p-nitrophenyl-N-acetyl-b-D-glucosamine) prepared in sodium citrate (pH 4.5) for one hour at 37°C. A 0.1 M Sodium carbonate/sodium bicarbonate buffer (pH 10) was used to stop the reaction and the assay was read at 405 nm. Degree of degranulation was reflected as a percent of b-hexosaminidase released \( = \frac{(\text{OD of supernatant})}{(\text{OD of total (supernatant + pellet))}} \times 100 \). Assays were performed in triplicate.

MAST CELL SURVIVAL ASSAY

To examine the effect of Pak1 loss on the survival of Nf1+/− mast cells in response to SCF, mast cells cultured as above were deprived of growth factors for 24 hours, and 5x10^5 cells were plated in 24-well dishes with serum free RPMI containing 1% glutamine
(BioWhittaker), 1.5% HEPES (BioWhittaker), and 2% penicillin/streptomycin (BioWhittaker) supplemented with 50ng/ml of SCF. The number of surviving cells was determined by trypan blue exclusion at 48 hours of culture post stimulation in a 37°C, 5% CO₂, humidified incubator. The number of apoptotic cells was measured by using the Annexin V-FITC Apoptosis detection kit (BD Pharmingen) and FACS™ analysis. Cells that stained double positive for both Annexin V and PI were counted as apoptotic. Assays were performed in triplicate.

**IN VIVO MAST CELL ACCUMULATION ASSAY**

Adapting methods described previously 169, Adult Nfl+/-; Pak1-/-, Nfl+/+; Pak1 +/-, Nfl +/-; Pak1+/, Nfl +/+; Pak1+/+ mice received a continuous infusion of various doses of SCF or vehicle (PBS) from microosmotic pumps (Alzet) placed under the dorsal back skin. Osmotic pumps were surgically placed under light avertin anesthesia. SCF or vehicle was released over 7 d at a rate of 0.5 µl/hour, and osmotic pumps were surgically removed on day 7 after sacrifice by cervical dislocation. To accurately identify cutaneous sections for quantitating changes in mast cell numbers in response to SCF, the dorsal skin was stained with a drop of Davidson Marking System® green tissue dye at the point of exit of SCF from the osmotic pump before removal of the pump. 3-cm sections of skin marked with tissue dye were removed, fixed in buffered formalin, and processed in paraffin-embedded sections. Specimens were stained with hematoxylin and eosin to assess routine histology and with Giemsa to identify mast cells. Cutaneous mast cells were quantitated in a blinded fashion by counting 2-mm² sections in proximity to the tissue dye stain. Cells were considered degranulated if there was a change from their
normal compacted and granular appearance resulting in an extensive dispersion of more than 15 extruded vesicles localized near the cell, or when there was an extensive loss of granule staining, giving the cell a “ghostly” or “hollow” look.170

**Nf1 CONDITIONAL KNOCKOUT ADOPTIVE TRANSFER**

*Krox20Cre;Nf1flox/flox* and *Krox20Cre;Nf1flox/-* mice were used as recipients to see if the adoptive transfer of *Nf1+/--;Pak1/-* hematopoietic system would alter the development or progression of plexiform neurofibromas. Briefly, 5x10⁶ whole bone marrow cells from either *Nf1+/-* or *Nf1+--;Pak1/-* mice were transplanted via tail vein injection into 6-8 week old *Krox20Cre;Nf1flox/flox* and *Krox20Cre;Nf1flox/-* mice after the recipients had been treated with a split dose of 1100 rads of ionizing radiation (700 rads followed by 400 additional rads 5 hours later). These animals were followed for over one year to assess the development of plexiform neurofibromas in the spinal nerve roots.

**GENERATION OF Krox20Cre;Nf1flox/-;Pak1/- ANIMALS**

*Krox20Cre;Nf1flox/-* mice on a C57BL/6J strain were intercrossed with *Pak1/-* mice also on a C57BL/6J strain. These animals were followed for over a year to assess to assess the development of plexiform neurofibromas in the spinal nerve roots. These studies were conducted with a protocol approved by the Indiana University Laboratory Animal Research Center.
DORSAL ROOT GANGLION DISSECTION AND MEASUREMENT

Immediately following sacrifice induced by CO inhalation, whole mice were perfused and fixed in 4% paraformaldehyde. The dorsal root ganglia and peripheral nerves were then dissected out under a dissection microscope. To evaluate the size of the dorsal root ganglion, an anatomic measurement of the dorsal root ganglia from the sciatic nerve was performed using calipers to measure the ganglion’s widest and longest dimensions. Using a formula which approximates spheroidal volume \((0.52 \times \text{width}^2 \times \text{length})\), the volume of the ganglia was determined.

HISTOLOGIC ANALYSIS OF DORSAL ROOT GANGLIA

To make detailed observations about the cellular composition and morphology of the dorsal root ganglia, paraffin sections were stained with hematoxylin and eosin (H&E). Given collagen accounts for approximately 60% of the dry weight of human plexiform neurofibromas, the tissue sections were also stained with Masson trichrome to identify collagen deposition. Additionally, to identify the presence of mast cells in the tissue, Alcian blue staining was performed.

GENERATION AND CULTURE OF PRIMARY FIBROBLASTS

Using an established method \(^75\), fibroblasts were derived from 13.5 days post coitus embryos of WT and Pak1-/- mice. Cells were maintained in culture using high glucose DMEM (Gibco BRL) supplemented with 10% fetal calf serum (HiClone), 1% glutamine (BioWhittaker), 1.5% HEPES (BioWhittaker), and 2% penicillin/streptomycin (BioWhittaker). Cells were cultured in a 37°C, 5% CO\(_2\), humidified incubator. All
assays utilized fibroblasts were from passage two to four. For all cellular and biochemical assays, fibroblasts were stimulated with human recombinant PDGF-BB (PeproTech) or human recombinant TGF-β (PeproTech). All experiments were conducted using at least three independent lines from each genotype.

**FIBROBLAST PROLIFERATION ASSAY**

$^{[3H]}$Thymidine incorporation assays were used to examine fibroblast proliferation, in a manner described previously $^{71}$. Briefly, fibroblasts were plated at a concentration of 2x10$^4$ cells in 200μL of media containing 10% fetal calf serum per well in 96 well tissue culture treated plates. After 24 hours, the cells were washed and media was replaced with DMEM without serum containing PBS as a vehicle controls, 50ng/mL PDGF-BB, or 2ng/mL TGF-β and incubated at 37°C in a 5% CO$_2$, humidified incubator. After 36 hours tritiated thymidine (PerkinElmer Life and Analytical Sciences) was added to each well 6 hours prior to harvest on glass filter fibers (Packard Instrument) and β-emission was measured.

**FIBROBLAST WOUND HEALING ASSAY**

To assess the migration of fibroblasts, we used an established wound healing assay protocol $^{71}$. 1x10$^5$ cells in 1mL of media containing 10% fetal calf serum were plated in a 12 well plate. After 24 hours, the cells were washed and media was replaced with DMEM without serum before incubation at 37°C in a 5% CO$_2$, humidified incubator. After 16 hours, the cells were washed and treated with 10μg/mL of Mitomycin C (Sigma-Aldrich) for 1 hour. The cells were then washed, and media was
replaced with DMEM without serum containing PBS as a vehicle control, 50ng/mL PDGF-BB, or 2ng/mL TGF-β. A wound was created using a plastic pipette tip across the diameter of the well, and the cells were incubated for 12 hours at 37°C and followed by time-lapse microscopic photography. After incubation, cells were stained with crystal violet solution, and the number of cells that invaded the wound was determined by using ImageJ (NIH) software.

FIBROBLAST COLLAGEN PRODUCTION ASSAY

To examine collagen production by fibroblasts after stimulation by PDGF-BB or TGF-β, the Sircol™ soluble collagen assay was used. Confluent fibroblast cultures on 10cm tissue culture dishes were stimulated for 48 hrs with PBS as a vehicle control, 50ng/mL PDGF-BB, or 2ng/mL TGF-β. After stimulation, 200µL of the media were incubated with the Sircol™ dye reagent. Dye collagen complexes were resolublized by addition of alkali reagent and OD readings were made on a microplate reader at a wavelength of 540nm.

FIBROBLAST APOPTOSIS ASSAY

To determine the effects of PDGF-BB and TGF-β on fibroblast survival, TUNEL staining with the APO-DIRECT™ kit (BD Pharmingen) was used. 1x10^5 cells in 2mL of media containing 10% fetal calf serum were plated on a 6 well plate. After 24 hours, the cells were washed and media without serum containing PBS as a vehicle control, 50ng/mL PDGF-BB, or 2ng/mL TGF-β was added. After 72 hours, the cells were removed from the wells by treatment with 0.1% Trypsin-EDTA (Gibco BRL) and fixed
in a 1% w/v paraformaldehyde in PBS. After fixation, the cells were stained with the APO-DIRECT™ kit components and analyzed by flow cytometry.

CONFOCAL ANALYSIS OF FIBROBLAST ACTIN CYTOSKELETON

To evaluate the F-actin cytoskeleton in fibroblasts, cells were prepared and stimulated as described above for wound healing assays, with the fibroblasts on coverslips rather than tissue culture plates. After 4 hours of incubation at 37°C in 5% CO₂, the fibroblast covered coverslips were placed into 3.7% formaldehyde solution for fixation. Fixed cells were treated with 0.01% Triton X-100 (Sigma-Aldrich in PBS for 5 minutes at 25°C, washed, and then incubated with 160nM Alexa Fluor® 488 Phalloidin (Invitrogen) for 20 minutes at 25°C prior to mounting with DAPI. Cells were then analyzed via confocal microscope with the Zeiss UV LSM-510 system.

FIBROBLAST IMMUNOBLOTTING

Whole cell protein extracts were obtained from fibroblasts stimulated with 50ng/mL PDGF-BB, or 2ng/mL TGF-β in lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA pH 8.0, 1% Triton X-100, 1mM PMSF, 1mM NaF, 1mM Na₃VO₄, 10% glycerol and Complete protease inhibitor), and equivalent amounts of protein were electrophoresed on 10% SDS-PAGE gels, transferred to nitrocellulose membranes (Amersham Biosciences), and detected by Western blotting using the ECL Plus system (Amersham Biosciences). Antibodies used were Phospho-p44/42 MAPK (Thr202/Tyr204) (197G2) Rabbit mAb (Cell Signaling Technology), p44/42 MAP Kinase Antibody (Cell Signaling Technology), Phospho-Cofilin (Ser3) polyclonal
antibody (Cell Signaling Technology), Cofilin polyclonal antibody (Cell Signaling Technology), Phospho-Filamin A (Ser2152) polyclonal antibody (Cell Signaling Technology), Filamin A polyclonal antibody (Cell Signaling) Monoclonal β-actin antibody (clone AC-15) (Sigma-Aldrich).

**IN VIVO FIBROBLAST INVASION ASSAYS**

Adapting a method described previously, we used a Cultrex™ plug assay to evaluate the invasion of fibroblasts *in vivo* in response to PDGF-BB or TGF-β. The Cultrex™ media (R&D Systems) was thawed at 4°C for 24h and mixed with PBS as a vehicle control, 200ng/mL PDGF-BB, or 10ng/mL TGF-β. 300μL of vehicle containing Cultrex™ or 300μL of growth factor containing Cultrex™ were injected subcutaneously into the left or right groin of WT or Pak1-/- mice, respectively. The plug was removed on day 7 and was frozen immediately on dry ice. Tissues were sectioned and stained with H&E to assess histology. The number of invaded cells per high power field was quantitated by using ImageJ software. At least 3 mice per genotype were examined.

**BLEOMYCIN INDUCED PULMONARY FIBROSIS MODEL**

Harrison described a model system where continuous release of bleomycin sulfate would induce a fibrotic reaction in mice that mimicked human pulmonary disease. We implanted microosmotic pumps (Alzet) containing PBS or 125mg/kg/day bleomycin subcutaneously in the dorsum of lightly anesthetized WT and Pak1-/-mice. 28 days after surgery, mice were sacrificed, bronchoalveolar lavage was performed and the lungs removed. The right lung was minced and used to assess total collagen content using the
Sircol™ collagen assay described above. The left lung was fixed in 1% formalin and sectioned for histological analysis. Both H&E to assess structure and Masson’s Trichrome to assess collagen deposition were performed.
RESULTS

ROLE OF Pak1 IN REGULATING STEM CELL FACTOR DEPENDENT FUNCTIONS IN Nf1 HAPLOINSUFFICIENT MAST CELLS

Generation of a Pak1 knockout mouse

In order to study the effects of Pak1 loss in primary cells, a Pak1−/− mouse was generated by targeted disruption of the Pak1 allele in embryonic stem (ES) cells (J.D. Allen and D.W. Clapp, submitted for publication). The resultant allele contains a neomycin cassette and is lacking 2 kb of genomic DNA encoding the p21-binding domain (Figure 3a). Pak1−/− mice are observed at the predicted Mendelian frequency and are viable and fertile. Pak1−/− mice have a normal lifespan and no noted hematopoietic defects. To verify that Pak1−/− mice produce no Pak1 protein, cell lysates isolated from WT and Pak1−/− BMMCs were subjected to Western blot using a Pak1 specific antibody (Figure 3b). To further document the absence of Pak1 protein being expressed at levels below detection of Western blot, RT-PCR was conducted to look for expression of the Pak1 mRNA transcript. As expected, Pak1 mRNA was detected in WT BMMCs, but no Pak1 mRNA was detected in Pak1−/− BMMCs (Figure 3c).
Figure 3

A. Disruption of the Pak1 gene

B. Pak1 (68 kDa)  \[\text{WT} \rightarrow \text{KO}\]

C. \[\text{WT} \rightarrow \text{KO}\]
Figure 3- Targeted disruption of the Pak1 allele. A) Partial restriction map of the native Pak1 gene (genomic locus), the targeting vector replacing the coding sequence of a portion of the N-terminus, including the p21-binding domain (PBD) and the inhibitory domain (ID) with the Neo-resistance gene in the anti-sense orientation (targeting vector), and the organization of the targeted Pak1 allele (targeted allele). The 1 kb genomic probe used for screening is indicated along with the expected sizes of the wild type (WT) and targeted HindIII fragments. B) Western blot analysis. WT and Pak1\(^{-/-}\) bone marrow-derived mast cell (BMMC) lysates were subjected to immunoblotting with anti-Pak1. The 68 kDa Pak1 protein is present in WT BMMCs and absent in the Pak1\(^{-/-}\) cells. C) RT-PCR analysis. After reverse transcription of isolated mast cell RNA, Pak1 cDNA was amplified by PCR from BMMCs to generate a 352 base pair fragment (corresponding to base pairs 306-658) in the WT cells, which is absent in the Pak1\(^{-/-}\) cells. GAPDH mRNA in WT and Pak1\(^{-/-}\) BMMCs is also shown.
**Intercross of Nf1<sup>+/−</sup> and Pak1<sup>−/−</sup> mice**

To test our hypothesis that Pak1 is an important mediator of hyperactive Ras signaling, we designed a breeding strategy to intercross Nf1<sup>+/−</sup> mice with Pak1<sup>−/−</sup> mice to generate Nf1<sup>+/−</sup>:Pak1<sup>−/−</sup> double mutant mice (Figure 4). Initial breedings of multiple C57BL/6 Nf1<sup>+/−</sup> and Pak1<sup>−/−</sup> founders generated Nf1<sup>+/−</sup>;Pak1<sup>+/+</sup> and Pak1<sup>+/−</sup> progeny. Intercrossing of the Nf1<sup>+/−</sup>;Pak1<sup>+/−</sup> mice from the F1 generation yielded four F2 genotypes that were used to generate mast cells for cellular and biochemical assays: Nf1<sup>+/−</sup>;Pak1<sup>+/+</sup> (wild type or +/+), Nf1<sup>+/−</sup>, Pak1<sup>−/−</sup>, and Nf1<sup>+/−</sup>:Pak1<sup>−/−</sup>.

**Loss of Pak1 reduces numbers of mast cell colonies**

Nf1 haploinsufficient mice have a characteristic increase in mast cell progenitors compared to wild type controls<sup>59</sup>. While genetic disruption of Pak1 does not cause any frank disruption of hematopoiesis, we were interested to see if Pak1 loss would affect the colony forming ability of mast cell progenitors. 2x10<sup>4</sup> low-density mononuclear cells (LDMNC) from bone marrow were cultured in methylcellulose with growth factors for 21 days to generate mast cell colonies and then scored. As expected, more mast cell colonies were found in Nf1<sup>+/−</sup> cultures than wild type cultures (Figure 5). Loss of Pak1 caused a significant decrease in the number of mast cell forming units compared to wild type controls. Additionally, Nf1<sup>+/−</sup>:Pak1<sup>−/−</sup> LDMNC generated significantly fewer mast cell colonies compared to Nf1<sup>+/−</sup> cultures, close to a level seen in wild type controls.
Figure 4

\[ Nf1^{+/+} \times Pak1^{-/-} \]

\[ +/+ \]
\[ Nf1^{+/+} \]
\[ Pak1^{-/-} \]
\[ Nf1^{+/+};Pak1^{-/-} \]
Figure 4- Genetic intercross of Nf1<sup>+/−</sup> and Pak1<sup>−/−</sup> mice. The four F2 genotypes generated (+/+; Nf1<sup>+/−</sup>; Pak1<sup>−/−</sup>; and Nf1<sup>+/−</sup>; Pak1<sup>−/−</sup>) were used to generate BMMCs for use in in vitro biochemical and cellular assays as well as in vivo whole animal studies to investigate the role of Pak1 in mediating Nf1 haploinsufficient phenotypes.
Figure 5

![Bar graph showing the number of colonies per animal for different genotypes.](image)

- 
- **Nfl+/−**
- **Pak1−/−**
- **Nfl+/− Pak1−/−**
Figure 5- Loss of Pak1 reduces mast cell colony forming unit ability. Low-density mononuclear cells (2x10^4) were plated for the growth of CFU-Mast cell in methylcellulose supplemented with 20% FCS, 2.5ng/mL IL-3, and 10ng/mL of SCF. After 21 days of incubation, CFU-Mast were enumerated using indirect microscopy and normalized to the cellularity of both femurs, tibias, and iliac crests. This total is expressed above as colony number/animal. Each value represents the mean and the error bars represent the standard error of the mean of 3 independent experiments. * indicates p<0.05 compared to WT control and ** indicates p<0.05 compared to Nf1^+/− control using Student’s unpaired T test.
Loss of *Pak1* does not affect expression of mast cell maturation markers

To investigate whether genetic disruption of *Pak1* does not influence mast cell development in intercrossed mast cells, low-density mononuclear bone marrow cells in the presence of serum and IL-3 were cultured for 4-5 weeks and expression of the c-kit receptor and FcεRI receptor was examined. Fluorescence cytometry analysis of the F2 progeny demonstrated equivalent expression of both c-kit and FcεRI receptors in all genotypes (Figure 6). Further, the cells had typical cellular morphology and staining of cytoplasmic granules upon Alcian Blue/Saffranin-O staining (data not shown). Collectively, the fluorescence cytometry and histological data indicate that alterations in Pak1 expression do not influence c-kit expression or mast cell development in cells that are WT or haploinsufficient at the *Nf1* locus.

Hyperproliferation of *Nf1*+/− bone marrow derived mast cells is dependent on a Pak1/MAPK pathway

Given previous work demonstrating elevated Pak kinase activity in *Nf1*+/− mast cells, as well as a pathological increase in *Nf1*+/− mast cell proliferation through Ras-MAPK signals 60, a combination of genetic and pharmacologic experiments were conducted to test the functional consequences of Pak1 loss on BMMCs. Proliferation was assessed by Trypan blue exclusion at the time SCF was added (day 0) and after 72 h in culture. As anticipated, *Nf1*+/− BMMCs showed greater proliferation in response to SCF compared with wild-type cells (Figure 7, black bars). Genetic disruption of *Pak1*
Figure 6

-\textit{NfI}\textsuperscript{+/+}

-\textit{NfI}\textsuperscript{-/-}

-\textit{Pak1}\textsuperscript{-/-}

-\textit{NfI}\textsuperscript{-/-};\textit{Pak1}\textsuperscript{-/-}
Figure 6- Loss of *Pak1* does not affect expression of important mast cell maturation markers. Mast cells were cultured for 4 weeks, and expression of c-kit and FcεRI were measured by incubation with anti-IgE followed by FITC-conjugated anti-mouse IgG, as well as PE-conjugated anti-c-kit antibodies. Double positive cells (upper right quadrant) are mature mast cells, expressing both c-kit and FcεRI. Data shown are representative of 6 independent lines from each genotype.
resulted in a significant decrease in proliferation at 72 hours in $Nf1^{+/\text{c}}$ cells ($p<0.005$), implicating Pak1 as a critical mediator of $Nf1$ haploinsufficient BMMC hyperproliferation. Further, $Pak1^{-/-}$ BMMCs had reduced proliferation (~60%) at 72 hours compared to wild-type cells ($p<0.05$), suggesting that Pak1 is important for regulating proliferation in the setting of normal Ras activity as well.

To link this phenotype to a particular MAPK pathway, concomitant proliferation experiments of cultured mast cells were performed in the presence or absence of 10µM PD98059, a selective inhibitor of Mek1 activity (Figure 7, white bars) or 10µM SB203580, a selective inhibitor of p38 MAPK (Figure 7, striped bars). Addition of p38 inhibitor SB203580 did not affect the proliferation of BMMCs of any genotype, indicating that p38 has little control over BMMC growth. Conversely, inhibition of Mek by PD98059 caused significant decreases in mast cell proliferation in the context of normal $Pak1$ (~100% and 150% decreases for WT and $Nf1^{+/\text{c}}$ BMMCs, respectively). Importantly, Mek inhibition did not significantly affect proliferation of Pak1 null cells, regardless of $Nf1$ genotype. Collectively, these data imply that Pak1 interacts with the Mek/Erk MAPK pathway in $Nf1^{+/\text{c}}$ mast cells to selectively regulate proliferation.

**Loss of Pak1 corrects MAPK hyperactivation in $Nf1$ haploinsufficient BMMCs**

To establish the role of Pak1 signaling in the activation of the Ras-Raf-Mek-Erk signaling pathway and to identify the specific MAPK residues that are phosphorylated, BMMCs were stimulated with SCF and assayed for activated MAPK pathway members by using phospho-specific antibodies after Western blotting. First, Erk1/2
Figure 7

![Bar graph showing percent input for different genotypes and treatments.]

- **+DMSO**
- **+SB203580 (p38 inhibitor)**
- **+PD98095 (Mek1 inhibitor)**
Figure 7- Pak1 regulates the increased proliferation of Nf1+/- mast cells in cooperation with Mek/Erk. Mast cells were starved overnight in RPMI and plated in a 24-well plate at 3x10^5 per well in triplicate samples after treatment with DMSO (control; black bars), 10µM of selective p38 inhibitor SB203580 (striped bars), or 10µM of selective Mek1 inhibitor PD98059 (white bars). Cells were then stimulated with 25ng of SCF for 72 hours, and viable cells were measured by trypan blue exclusion. Results are expressed as percent of input number of cells at 72 hours post stimulation. Each value represents the mean and the error bars represent the standard error of the mean of 6 independent experiments. * indicates p<0.05 compared to WT control, ** indicates p<0.05 compared to Nf1+/- control, and # indicates p<0.05 compared to DMSO treated cells within a genotype using Student’s unpaired T test.
phosphorylation was measured. Consistent with previous studies, BMMCs have a 2.5-fold increase in phosphorylated (activated) Erk1/2 (Figure 8). Pak1 mast cells had decreased Erk activation, and importantly genetic disruption of Pak1 fully corrects the hyperphosphorylation of Erk1/2 in Nf1 mast cells to that of wild-type controls, which correlates with the correction in proliferation (Figure 7).

Frost et al. previously established that Pak1 directly activates Mek at serine residue 298 in NIH3T3 cells. Immunoblotting of lysates from SCF stimulated Nf1 BMMCs revealed increased phosphorylation of Mek1 at this established target residue of direct Pak1 kinase activity compared to wild type controls (Figure 9). Nf1;Pak1 mast cells showed greatly diminished phospho-Ser 298 Mek1 levels compared to Nf1 cells (Figure 9). In a similar manner, in Nf1 BMMCs Mek phosphorylation at Ser 217/222, the site of Raf-1 dependent activation, is increased compared to wild type (Figure 10). In Nf1;Pak1 mast cells stimulated with SCF, Mek Ser 217/222 activation is reduced compared to Nf1 cells, close to wild type control levels (Figure 10). Raf-1 has been described in multiple systems as a direct substrate of Pak at serine residue 338. These studies establish that Pak1, a downstream mediator of PI-3 K/Rac signaling, is biochemically linked to the classical Ras/Raf/Mek/Erk pathway in primary cells. Together with the proliferation data displayed in Figure 7, we establish a crucial role for Pak1 kinase activity in regulating the increased proliferation of Nf1 BMMCs by relaying signals to the Mek/Erk pathway.
Figure 8
Figure 8- Erk activation is reduced in cells that lack Pak1. Mast cells were serum starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 2 minutes following stimulation. 100µg of protein were used for each time point. Levels of active Erk1/2 were determined by immunoblotting using phospho-specific antibodies. Levels of total Erk1/2 are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments. Each value represents the mean and the error bars represent the standard error of the mean of three independent experiments.
Figure 9

![Graph showing % increase over baseline with SCF stimulation and protein levels for phospho-MEK Ser298 and Total Mek1 under different conditions: +/+, Nfl+/-, Pak1/-, Nfl+/-, Pak1/-]
Figure 9- Phosphorylation of Mek1 at Ser 298 is reduced in Pak1−/− cells. Mast cells were serum starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 2 minutes following stimulation. 100µg of protein were used for each time point. Levels of active Mek1 were determined by immunoblotting using phospho-specific antibodies. Levels of total Mek1 are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments. Each value represents the mean and the error bars represent the standard error of the mean of 3 independent experiments.
Figure 10

![Graph showing percentage increase over baseline with SCF stimulation conditions.

SCF stimulation: -,-,+,-,+,-,+,

Phospho-MEK Ser217/221

Total Mek1

+/+ Nfl+/+ Pak1/- Nfl+/- Pak1/-]
**Figure 10- Pak1 loss reduces phosphorylation of Ser217/221 on Mek1.** Mast cells were serum starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 2 minutes following stimulation. 100µg of protein were used for each time point. Levels of active Mek1 were determined by immunoblotting using phospho-specific antibodies. Levels of total Mek1 are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments. Each value represents the mean and the error bars represent the standard error of the mean of three independent experiments.
A Pak1/p38 pathway regulates increased migration of \( Nf1^{+/—} \) mast cells

The recruitment of mast cells from the peripheral blood to sites of developing tumors is believed to be an early and required process in the formation of plexiform neurofibromas \(^{30,62,174} \). \( Nf1^{+/—} \) BMMCs have a PI3K- Rac-dependent gain-in-function in SCF mediated haptotaxis compared to wild type BMMCs \(^{62} \). Therefore, we questioned whether loss of Pak1 would be sufficient to correct the pathological increase in migration of \( Nf1^{+/—} \) BMMCs toward SCF. To explore these questions transwells were coated with recombinant fibronectin fragment CH296 (Takara Biosystems) and migration assays were performed in response to 25ng/mL of SCF. Following 4 hours of incubation in the transwells, the number of mast cells that had migrated to the bottom surface of the fibronectin-coated membrane was counted after staining the cells with crystal violet. BMMCs that were stimulated with media alone showed fewer than 5 cells per high power field had migrated to the lower side of the membrane (data not shown). As expected, increased numbers of \( Nf1^{+/—} \) mast cells migrate toward SCF compared to wild type mast cells (Figure 11, black bars). Also, loss of Pak1 causes a decrease in migration compared to wild type BMMCs (p<0.05). Notably, \( Nf1^{+/—};Pak1^{—/—} \) BMMCs have decreases in the number of migrated mast cells compared to BMMCs haploinsufficient at the \( Nf1 \) locus, indicating that the increased migration in \( Nf1^{+/—} \) mast cells is Pak1 dependent.

Previous studies have established that mast cells migrate in response to SCF in a p38-dependent manner \(^{175-177} \). To test if the gain-in-function phenotype for \( Nf1^{+/—} \) mast cell migration was the result of communication from Pak1 to p38, BMMCs were treated with 10μM of the selective inhibitor of p38 SB203580 (Figure 11, striped bars), 10μM of
the selective inhibitor of Mek1 PD98059 (Figure 11, white bars), or the vehicle only and stimulated as described above. Interestingly, treatment of BMMCs with p38 inhibitor results in a significant decrease in migration of wild type and \( \text{NfI}^{+/} \) mast cells (by 28% and 41%, respectively), but does not further reduce migration of \( \text{Pak1}^{-/-} \) or \( \text{NfI}^{+/};\text{Pak1}^{-/-} \) mast cells, implying that SCF stimulates \( \text{NfI}^{+/} \)BMMC hyperactive migration through a Pak1/p38 pathway. Treatment with the Mek1 inhibitor PD98059 did not affect the migration of BMMCs to SCF, as reported previously.175

\( \text{Pak1} \) is required for the increase in p38 phosphorylation seen in \( \text{NfI} \) haploinsufficient mast cells

To establish a biochemical correlate to the functional results shown in Figure 9, which implicate a Pak1/p38 axis in mediating the increased migration of \( \text{NfI}^{+/} \) mast cells, BMMCs were stimulated with SCF and examined for levels of activated phospho-p38 (R180/Y182). Figure 12 shows that \( \text{NfI}^{+/} \) BMMCs have increased activated p38, consistent with the results of Figure 9. Additionally, loss of \( \text{Pak1} \) greatly diminishes phospho-p38 levels after SCF stimulation, providing biochemical evidence that SCF activates a Pak1/p38 pathway in mast cells. This pathway is hyperactivated in \( \text{NfI}^{+/} \) mast cells and leads to increased migration. Therefore, molecular targeting of this pathway could potentially inhibit the recruitment of \( \text{NfI}^{+/} \) mast cells to sites of growing neurofibromas and delay or prevent tumor development.
Figure 11

- +DMSO
- +SB203580 (p38 inhibitor)
- +PD980959 (Mek1 inhibitor)
Figure 11- Increased migration of Nf1+/− mast cells is mediated through a Pak/p38 pathway. Mast cells were starved overnight in RPMI without serum and plated in the upper well of a transwell chamber at 1x10^5 per well in triplicate samples after treatment with DMSO (control; black bars), 10µM of selective p38 inhibitor SB203580 (striped bars), or 10µM of selective Mek1 inhibitor PD98059 (white bars). Cells were then stimulated with 25ng of SCF in the lower chamber for 4 hours, and mast cells that had migrated to the bottom surface of the CH296-coated membrane in response to SCF were counted after staining the cells with crystal violet. Results are expressed as cells per 20x high power field. Each value represents the mean and the error bars represent the standard error of the mean of 6 independent experiments. * indicates p<0.05 compared to WT control, ** indicates p<0.05 compared to Nf1+/− control, and # indicates p<0.05 compared to DMSO treated cells within a genotype using Student’s unpaired T test.
Figure 12

% increase over baseline

SCF stimulation

Phospho-p38

Total - p38

+/+  Nf1+/+  Pak1/-  Nf1+/-  Pak1/-
**Figure 12-** *Pak1*<sup>−/−</sup> Mast cells have diminished p38 activation. Mast cells were serum starved overnight, stimulated with SCF, and cell lysates isolated at 0 and 5 minutes following stimulation. 100μg of protein were used for each time point. Levels of active p38 were determined by Western blotting using phospho-specific antibodies. Level of total p38 is shown as a loading control. Western blot of the results is shown and is a representative of three independent experiments. Each value represents the mean and the error bars represent the standard error of the mean of three independent experiments.
Pak1 regulates F-actin content and organization in a p38-dependent manner

Actin polymerization at the cell front leads to the early extension of plasma membrane, which is necessary for cell migration\textsuperscript{178}. c-Kit-mediated mast cell migration is highly dependent on alterations and activation of the actin cytoskeleton by Ras and PI-3K\textsuperscript{164,179,180}. Additionally, other groups have used overexpression systems to describe a role for Pak1 in the regulation of actin dynamics and migration in murine embryonic fibroblasts\textsuperscript{181}, murine bone marrow derived macrophages\textsuperscript{138}, and others. Mast cells deficient in Rac2 (a direct activator of Pak1) have diminished actin cytoskeleton dependent functions\textsuperscript{164}. Based on the established association of increases in F-actin content with the increases in migration seen in Nf1\textsuperscript{+-} BMMCs\textsuperscript{62}, we hypothesized that the Pak1-dependent decrease in Nf1\textsuperscript{+-} BMMC migration (Figure 11) stemmed from a disruption of the F-actin content and/or organization in these cells.

To determine if Pak1 loss affects BMMC F-actin content, SCF-stimulated BMMCs were stained with phalloidin and analyzed using fluorescence cytometry and confocal microscopy. Figure 13a-l shows representative confocal images of phalloidin and DAPI co-stained BMMCs. At a single cell level, confocal images reveal that at baseline (Figure 11d) and after SCF stimulation (Figure 13e), Nf1\textsuperscript{+-} BMMCs have increased phalloidin staining compared to wild type BMMCs (Figure 13a and 13b), while Pak1\textsuperscript{-/-} cells (Figure 13h) have decreased F-actin compared to wild type cells (Figure 13b) after SCF stimulation. Consistent with the functional migration data (Figure 11), the Nf1\textsuperscript{+-};Pak1\textsuperscript{-/-} BMMCs (Figure 13k) have a reduction in F-actin levels compared to Nf1\textsuperscript{+-} cells (Figure 13e) after SCF stimulation. Figure 13m details a formal
quantification of the phalloidin intensity from six independent experiments utilizing FACS™ to quantitate F-actin content on SCF stimulated BMMCs.

As shown in Figure 11, inhibition of p38 MAPK leads to decreases in wild type and Nf1+/− mast cell migration, but does not affect the migration of Pak1−/− cells. To see if the observed differences in the cytoskeleton after SCF stimulation were linked to p38 activity, we examined the F-actin content and organization of BMMCs that were incubated with 10µM SB203580 for 2h before stimulation. As shown in Figure 13m, the total F-actin content in Nf1+/− BMMCs was decreased after SB203580 treatment (striped bar). Similar to the migration results in figure 11, inhibition of p38 MAPK did not significantly affect the total F-actin content of Nf1+/−;Pak1−/− BMMC after SCF stimulation (Figure 13m); indicating that a hyperactive Pak1/p38 pathway regulates F-actin formation in Nf1+/− mast cells. Confocal analysis of phalloidin stained BMMCs pretreated with SB203580 shows that the inhibition of p38 in wild type (Figure 13c) and Nf1+/− mast cells (Figure 13f) disrupts the organization of F-actin to a pattern similar to that seen in BMMCs lacking Pak1 (Figures 13i and 13l).

Disruption of Pak1 reduces granule release from Nf1+/− mast cells

The molecular processes that regulate the degranulation of preformed mediators in mast cells have implications in the development of neurofibromas, since Nf1+/− mast cells have increased release of stored granules in vitro61 as well as in NF1 patient samples9.
Figure 13

<table>
<thead>
<tr>
<th>+DMSO</th>
<th>+SCF</th>
<th>+SCF/SB203580</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>b.</td>
<td>e.</td>
</tr>
<tr>
<td>d.</td>
<td>e.</td>
<td>f.</td>
</tr>
<tr>
<td>g.</td>
<td>h.</td>
<td>i.</td>
</tr>
<tr>
<td>j.</td>
<td>k.</td>
<td>l.</td>
</tr>
</tbody>
</table>

+++

Nf1+/-

Pak1-/-

Nf1+/-;Pak1-/-
Figure 13m

Fold increase over baseline

- +/+  
- Nf1+/-  
- Pak1-/-  
- Nf1+/ P,ak1-/-  

- +DMSO  
- +SB203580
Figure 13- Pak1 and p38 cooperate to regulate activation and organization of the F-actin cytoskeleton. Mast cells were starved overnight in RPMI and plated in the upper well of a transwell chamber at 1x10^5 per well in triplicate samples after treatment with DMSO or 10µM of selective p38 inhibitor SB203580. Cells were then stimulated with 25ng of SCF in the lower chamber for 30 minutes, and mast cells were removed from the upper chamber for phalloidin staining of the F-actin cytoskeleton. A-L) Representative micrographs of phalloidin stained mast cells analyzed with the Zeiss UV LSM-510 confocal microscope system. Green=phalloidin stain, blue=DAPI nuclear stain. Original magnification x400. M) Fluorescence intensity of phalloidin stained mast cells, determined by fluorescence cytometry. Data are expressed as fold increases over wild type levels, each value represents the mean and the error bars represent the standard error of the mean of 6 independent experiments. * indicates p<0.05 compared to WT control, ** indicates p<0.05 compared to Nf1^+/− control, and # indicates p<0.05 compared to DMSO treated cells within a genotype using Student’s unpaired T test.
To establish a role for Pak1 in regulating the gain-in-function of degranulation in Nfi1+/− mast cells, we evaluated the release of β hexosaminidase in response to SCF and IgE receptor stimulation. Consistent with published reports 61, Nfi1+/− BMMCs have a significant increase (37%) in β hexosaminidase release over wild type cells (Figure 14). However, Nfi1+/−;Pak1−/− BMMCs have a reduction in degranulation compared to Nfi1+/− cells, back to the levels of wild type controls. The Mek/Erk MAPK pathway has been implicated in regulating mast cell degranulation 182; however, treating mast cells with SB203580 to inhibit p38 does not affect mast cell mediator release 183. In contrast to the proliferation data shown in Figure 7, treatment of Pak1 null BMMCs with PD98059 did reduce the amount of β hexosaminidase released after IgE stimulation compared to DMSO treated controls (Figure 15), implying that for degranulation, the Pak1 and Mek/Erk pathways operate independently. These findings support a role for Pak1 in mediating signals that control the hyperactive degranulation phenotype seen in mast cells haploinsufficient at Nfi.

Loss of Pak1 does not significantly affect mast cell survival

Previous reports have established SCF as a survival factor for mast cells 53. Given the finding that Nfi1+/− mast cells have increased, PI3-K dependent survival in response to SCF stimulation 75, and that Pak1 has been described as anti-apoptotic in multiple cellular lineages 143,184,185, we examined whether loss of Pak1 would affect the survival of SCF
Figure 14

![Bar graph showing the percent wild type for different genotypes: +/-, Nf1 +/-, Pak1 +/-, and Nf1 +/- Pak1 +/- with statistical significance marked by asterisks.](image-url)
Figure 14- Increased degranulation in \(Nf1^{+/−}\) mast cells is corrected by disruption of Pak1. Mast cells were sensitized with anti-DNP IgE monoclonal antibody and assayed for degranulation by measuring the release of \(\beta\) hexosaminidase release following treatment with 25ng/mL of SCF and 30ng/mL of DNP-HSA IgE receptor stimulation. Values express the mean percent difference of the wild type response and the error bars represent the standard error of the mean of 4 independent experiments. * indicates \(p<.05\) compared to WT control, ** indicates \(p<.05\) compared to \(Nf1^{+/−}\) control using Student’s unpaired T test.
Figure 15

![Bar chart showing percent release with different conditions.](chart.png)
Figure 15- Pak1 and Mek1/Erk operate in parallel pathways to regulate mast cell
granule release. Mast cells were sensitized with anti-DNP IgE monoclonal antibody and
treated with 10μM of selective Mek1 inhibitor PD98059 for 2h. Cells were assayed for
degranulation by measuring the release of β hexosaminidase release following treatment
with 30ng/mL of DNP-HSA IgE receptor stimulation. The percent release was calculated
using the equation: (OD of supernatant/OD of pellet + OD of supernatant) x 100. Values
represent the mean from one representative experiment of three.
stimulated mast cells. As expected, $Nf1^{+/−}$ mast cells have reduced apoptosis 48 hours after SCF stimulation compared to wild type cells (Figure 16); however, genetic disruption of $Pak1$ did not significantly affect the survival of BMMCs, regardless of $Nf1$ genotype. These experiments demonstrate that, contrary to other cellular studies, $Pak1$ does not regulate the survival responses induced by c-Kit stimulation in mast cells.

Cutaneous expansion and degranulation of mast cells in $Nf1^{+/−}$ mice in response to SCF is $Pak1$-dependent

*In vivo* mast cell expansion in response to local injection of SCF occurs secondary to local proliferation. In order to determine if our *in vitro* findings are relevant in a more physiologic system, we examined cutaneous mast cell accumulation *in vivo* after local administration of SCF. The progeny generated from the $Nf1^{+/−}$ and $Pak1^{−/−}$ genetic intercross were implanted with slow release microosmotic pumps to deliver 10 µg/kg/day of SCF or PBS (as a vehicle control) continuously. Overlying skin sections were harvested 7 days later and stained with Giemsa to identify mast cells.

Representative histological sections from animals treated with SCF and stained with Giemsa are shown in Figure 17c-f. Figure 17a shows quantitative results scoring the number of mast cells in the sections per mm$^2$. $Pak1$ null mice had a significant decrease in cutaneous mast cells compared to wild type mice after SCF delivery (Figure 17a). $Nf1^{+/−}$ mice had a greater accumulation ($>80\%$ increase) of mast cells at the site of SCF infusion compared with wild type control mice (Figure 17a). In keeping with the *in vitro* proliferation data (Figure 7), this excess expansion of cutaneous mast cells in $Nf1^{+/−}$ mice
Figure 16

[Bar graph showing percent Annexin V PI double positive for different genotypes: +/+ > Nf1+/- > Pak1-/- > Nf1+/-; Pak1-/-]

* Denotes statistical significance.
Figure 16- Loss of Pak1 does not affect the survival of wild type or Nf1+/− mast cells.

Bone marrow-derived mast cells were starved overnight in RPMI, plated in triplicate samples, and then stimulated with 25 ng/mL SCF. Cells were assayed for apoptosis at each indicated time point by Annexin V/PI staining and analyzed by fluorescence cytometry. Cells that were doubly positive for both Annexin V and PI were considered apoptotic. Values represent the mean and the error bars represent the standard error of the mean 1 of 3 independent experiments performed in quadruplicate. * indicates p<0.05 compared to WT control using Student’s unpaired T test.
was corrected in Nf1\textsuperscript{+/−};Pak1\textsuperscript{−/−} mice. SCF infusion into Nf1\textsuperscript{+/−} mice causes increased degranulation of local mast cells compared to wild type mice \textsuperscript{61}. We reproduced this result (Figure 17b, and 17d, open arrows) and also found that loss of Pak1 corrects this phenotype by significantly reducing the percentage of degranulating mast cells in the skin of Nf1\textsuperscript{+/−};Pak1\textsuperscript{−/−} mice. Our observations suggest that the biochemical mechanisms identified \textit{in vitro} resulting from genetic disruption of Pak1 in mast cells are biologically operative \textit{in vivo}.
Figure 17a

![Bar graph showing mast cell counts for different genotypes: +/+, Nfl+/-, Pak1/-, and Nfl+/-; Pak1/-.

Mast Cells/mm²

+/-  Nfl+/-  Pak1/-  Nfl+/-; Pak1/-

* Significant difference.

** Highly significant difference.
Figure 17b
e

+/+

Nf1+/-

d

Pak1-/-

Nf1+/-;Pak1-/-

f

Figure 17- Effect of genetic inactivation of *Pak1* on accumulation of cutaneous *Nf1*+/− mast cells in response to local administration of SCF *in vivo*. SCF was delivered *in vivo* via a microosmotic pump on the middorsum at 10ug/kg/day. Skin sections at the site of SCF administration were fixed and stained with hematoxylin and eosin to assess routine histology along with Giemsa to identify mast cells. A) Cutaneous mast cells were quantitated in a blinded fashion by counting 2mm² sections, and B) The percentage of degranulating mast cells present per 2mm² section was calculated. Representative sections are displayed in C-F). Resting mast cells in C-F) are marked with an ✶, degranulating mast cells in C-F) are marked with an open arrow. Values in A) and B) represent the mean of 3 independent experiments each using 3 mice per genotype and the error bars represent the standard error of the mean. * indicates p<0.05 compared to WT control and ** indicates p<0.05 compared to *Nf1*+/− control using Student’s unpaired T test.
ROLE OF \textit{Pak1} IN PLEXIFORM NEUROFIBROMA FORMATION

Adoptive transfer of \(Nf1^{+/--}Pak1^{+/--}\) bone marrow into Schwann cell nullizygous recipients

Based on the results above which identified \textit{Pak1} as a regulator of gains-in-function associated with \(Nf1\) haploinsufficiency in mast cells, we hypothesized that Pak1 signaling in the hematopoietic compartment of the neurofibroma microenvironment could contribute to tumor formation \textit{in vivo}. To test this hypothesis, we transferred either \(Nf1^{++/--}\) (as a positive control) or \(Nf1^{++/--}Pak1^{+/--}\) bone marrow into mice with conditionally ablated \(Nf1\) alleles in the Schwann cell lineage. Two experimental groups of recipient mice were used. First, we used \(Krox20\text{Cre};Nf1^{flox/flox}\) mice, which are functionally WT in all non-Schwann cell lineages and do not spontaneously develop neurofibromas. Recent work has shown that transplantation of \(Nf1^{++/--}\) bone marrow into \(Krox20\text{Cre};Nf1^{flox/flox}\) mice is sufficient to stimulate neurofibroma development \cite{64}, therefore we hypothesized that transfer of \(Nf1^{++/--}Pak1^{+/--}\) bone marrow would not be permissive to allow tumor formation. Additionally, we used \(Krox20\text{Cre};Nf1^{flox/}\) as recipients, which contain a germline disruption of one copy of \(Nf1\) and a floxed allele susceptible to recombination in the Schwann cell lineage. \(Krox20\text{Cre};Nf1^{flox/}\) consistently develop plexiform neurofibromas around the spinal nerve roots within 8 months of life \cite{30,64}. We predicted that \(Krox20\text{Cre};Nf1^{flox/}\) mice reconstituted with \(Nf1^{++/--}Pak1^{+/--}\) bone marrow would prevent or delay the formation of tumors in these mice. A schematic of the experimental design is outlined in Figure 18.
Figure 18

Recipient mice

Krox20;Nf1<sup>box/box</sup>
Non-tumorigenic
Schwann cells Nf1<sup>−/−</sup>
Hematopoietic cells Nf1<sup>+/+</sup>
Fibroblasts Nf1<sup>+/+</sup>
Endothelial cells Nf1<sup>+/+</sup>

Krox20;Nf1<sup>box/−</sup>
Tumorigenic
Schwann cells Nf1<sup>−/−</sup>
Hematopoietic cells Nf1<sup>+/+</sup>
Fibroblasts Nf1<sup>+/+</sup>
Endothelial cells Nf1<sup>+/−</sup>

Bone marrow transplantation

Nf1<sup>−/−</sup>
or
Nf1<sup>−/−/Pah1<sup>−/−</sup></sup>

Bone marrow transplantation

Nf1<sup>+/−</sup>
or
Nf1<sup>−/−/Pah1<sup>−/−</sup></sup>

Measurements of tumor formation

Dorsal root ganglia /
Peripheral nerves
• DRG volume
• Histochemical stains
Figure 18- Neurofibroma formation experimental design. Schematic showing the genotypes of recipient mice, the genotypes of adoptively transferred cells following ionizing radiation of the recipients, and measurements obtained following transplantation.
Krox20Cre;Nf1^flox/flox mice reconstituted with Nf1^+/--;Pak1^-/- bone marrow develop plexiform neurofibromas

Following 1100 Rads of ionizing radiation, 5x10^6 whole bone marrow cells from Nf1^+/+ mice or Nf1^+/-;Pak1^-/- mice were transplanted into Krox20Cre;Nf1^flox/flox mice. These mice were followed after transplant for 12-15 months before they were sacrificed and investigated for tumor formation along the spinal nerve roots. There was no difference in post-transplant survival between the recipients of Nf1^+/+ marrow or Nf1^+/-;Pak1^-/- marrow (over 85% survival in both groups at 12 months). Necropsy of the spinal nerves showed enlargement of dorsal root ganglia in both recipients of Nf1^+/+ marrow as well as recipients of Nf1^+/-;Pak1^-/- marrow. Volumetric analysis of these dorsal root ganglia showed no significant changes in the volume of the dorsal root ganglia of the sciatic nerve (which is a common location for neurofibromas in Krox20Cre;Nf1^flox/-- mice) between recipients of Nf1^+/+ marrow versus recipients of Nf1^+/-;Pak1^-/- marrow (Figure 19).

Unexpectedly, histological examination of sections of dorsal root ganglia and proximal peripheral nerves from 100% of recipients of both of Nf1^+/+ bone marrow as well as 100% of recipients of Nf1^+/-;Pak1^-/- bone marrow revealed the presence of classical pathologic features of plexiform neurofibromas. These include disruptions of nerve root architecture and Schwann cells (Figure 20), increased angiogenesis and blood vessel presence in the nerve (Figure 20, red arrows), as well as substantial collagen deposition (Figure 21). Interestingly, while both recipients of both of Nf1^+/+ bone marrow and recipients of Nf1^+/-;Pak1^-/- bone marrow have increases in the number of infiltrating
Figure 19

![Bar graph showing DRG Volume (mm³) for different bone marrow genotypes. The graph compares NfI+/− and NfI+/−; Pak1−/− genotypes.]
Figure 19- *Krox20Cre;Nf1*<sup>fl/fl</sup> mice reconstituted with *Nf1*<sup>+/−;Pak1*<sup>−/−</sup> mice develop enlarged sciatic nerve dorsal root ganglia. *Krox20Cre;Nf1*<sup>fl/fl</sup> mice were sacrificed 12-15 months after transplantation with *Nf1*<sup>+/−</sup> or *Nf1*<sup>+/−;Pak1*<sup>−/−</sup> bone marrow and the spinal cord and nerve roots of each animal were dissected. The dorsal root ganglia dimensions were obtained by measurement with calipers and volume was determined by using the formula (0.52 x (width)<sup>2</sup> x (length)) to approximate spheroidal volume. Values represent the mean of 15 recipients of *Nf1*<sup>+/−</sup> marrow and 11 recipients of *Nf1*<sup>+/−;Pak1*<sup>−/−</sup> marrow, and error bars represent the standard error of the mean. No significant difference between the means of the two genotypes was found using Student’s unpaired T test.
Figure 20

Normal  \quad Nf1^{+/-}  \quad Nf1^{+/-};Pak1^{+/-}

Bone marrow genotype
Figure 20- *Krox20Cre;Nf1^{flax/flax}* mice reconstituted with *Nf1^{+/-};Pak1^{-/-}* bone marrow develop histologically identifiable plexiform neurofibromas. Representative hematoxylin and eosin (H&E) stained sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1^{flax/flax}* mice transplanted with either *Nf1^{+/-}* marrow or *Nf1^{+/-};Pak1^{-/-}* marrow. Blood vessels are identified by red arrows. Genotypes of donor bone marrow are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.
Figure 21

Normal  \( Nf1^{+/-} \)  \( Nf1^{+/-};Pak1^{-/-} \)

Bone marrow genotype
Figure 21- *Krox20Cre;Nf1^{flax/flax}* mice reconstituted with *Nf1^{+/+};Pak1^{-/-}* bone marrow have collagen deposition characteristic of plexiform neurofibromas. Representative sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1^{flax/flax}* mice transplanted with either *Nf1^{+/+}* marrow or *Nf1^{+/+};Pak1^{-/-}* marrow were stained with Masson’s trichrome to identify collagen content. Collagen is identified by bright blue staining. Genotypes of donor bone marrow are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.
Figure 22a

Normal  \( \text{Nf1}^{+/-} \)  \( \text{Nf1}^{+/-}; \text{Pak1}^{-/-} \)

Bone marrow genotype
Figure 22b

[Bar graph showing mast cell counts per HPF for different bone marrow genotypes]

Mast cells/HPF

Nf1+/-

Nf1+/-;Pak1-/-

Bone marrow genotype
Figure 22- *Krox20Cre;Nf1\textsuperscript{flx/flx}* mice reconstituted with *Nf1\textsuperscript{+/−};Pak1\textsuperscript{−/−}* bone marrow have reduced mast cell numbers present in plexiform neurofibromas.  A) Representative sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1\textsuperscript{flx/flx}* mice transplanted with either *Nf1\textsuperscript{+/−} marrow or *Nf1\textsuperscript{+/−};Pak1\textsuperscript{−/−} marrow were stained with Alcian blue to identify mast cell numbers. Mast cells are identified by red arrows. Genotypes of donor bone marrow are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.  B) Number of mast cells present in Alcian blue sections from 8 animals per genotype were quantitated by counting mast cells per high power field. Values represent the mean and the error bars represent the standard error of the mean. * indicates p<0.05 compared to *Nf1\textsuperscript{+/−} recipients using Student’s unpaired T test.
mast cells to the dorsal root ganglia (Figure 22a, red arrows), recipients of Nf1+/−;Pak1−/− bone marrow have a significant decrease (~38%) in the number of mast cells compared to recipients of Nf1+/− bone marrow (Figure 22b). Despite this decrease in mast cell number, reconstitution of Krox20Cre;Nf1fllox/flox mice with Nf1+/−;Pak1−/− bone marrow lead to similar outcomes in terms of neurofibroma development and structure as Krox20Cre;Nf1fllox/flox mice with Nf1+/− bone marrow, indicating that loss of Pak1 in the tumor microenvironment still permitted the hematopoietic compartment to induce neurofibroma formation.

Krox20Cre;Nf1fllox− mice reconstituted with Nf1+/−;Pak1−/− bone marrow develop plexiform neurofibromas

In a similar manner, irradiated Krox20Cre;Nf1flox/flox mice received bone marrow from Nf1+/− mice or Nf1+/−;Pak1−/− mice and were followed after transplant for 12-15 months before they were sacrificed and investigated for tumor formation along the spinal nerve roots. As with Krox20Cre;Nf1flox/flax recipients, Krox20Cre;Nf1flax− mice had similar post-transplant mortality (over 85% survival in both groups at 12 months) regardless of the genotype of transplanted marrow. Necropsy of the spinal nerves showed enlargement of dorsal root ganglia in both recipients of Nf1+/− marrow as well as recipients of Nf1+/−;Pak1−/− marrow. Volumetric analysis of these dorsal root ganglia showed no significant changes in the volume of the dorsal root ganglia of the sciatic nerve between recipients of Nf1+/− marrow versus recipients of Nf1+/−;Pak1−/− marrow (Figure 23).
Pathologic analysis demonstrated the presence of plexiform neurofibromas in 100% of Krox20Cre;Nf1\textsuperscript{flox/} mice transplanted with Nf1\textsuperscript{+/-};Pak1\textsuperscript{-/-} bone marrow. Recipients of Nf1\textsuperscript{+/-};Pak1\textsuperscript{-/-} bone marrow had very similar histological features as recipients of Nf1\textsuperscript{+/-} bone marrow, including disorganized cellular architecture (Figure 24), increased numbers of blood vessels (Figure 24, red arrows), and large deposits of collagen in the ECM (Figure 25). In contrast to the results shown in Figure 22b which describe a reduction in the number of mast cells present in neurofibromas found in Krox20Cre;Nf1\textsuperscript{flox/} mice transplanted with Nf1\textsuperscript{+/-};Pak1\textsuperscript{-/-} bone marrow, Krox20Cre;Nf1\textsuperscript{flox/} mice transplanted with Nf1\textsuperscript{+/-};Pak1\textsuperscript{-/-} bone marrow have equal numbers of mast cells as Krox20Cre;Nf1\textsuperscript{flox/} mice transplanted with Nf1\textsuperscript{+/-} bone marrow (Figure 26). These experiments using adoptive transfer of bone marrow into Krox20Cre;Nf1\textsuperscript{flox/} mice demonstrate that disruption of Pak1 in the hematopoietic system is not sufficient to counteract the neurofibroma stimulating phenotype of the Nf1 haploinsufficient microenvironment.

Genetic disruption of Pak1 in Krox20Cre;Nf1\textsuperscript{flox/} mice does not prevent neurofibroma formation

Adoptive transfer of Nf1\textsuperscript{+/-};Pak1\textsuperscript{-/-} bone marrow into Krox20Cre;Nf1\textsuperscript{flox/flax} or Krox20Cre;Nf1\textsuperscript{flax/} mice resulted in the development of neurofibromas similar to mice transplanted with Nf1\textsuperscript{+/-} bone marrow. Therefore, we were interested in the tumor forming ability of conditionally disrupted Nf1 mice that lacked Pak1 in all lineages, not just the hematopoietic compartment. Genetic intercross of Krox20Cre;Nf1\textsuperscript{flox/} mice with
Figure 23

Bone marrow genotype

DRG volume (mm$^3$)

$Nfl^{+/−}$

$Nfl^{+/−};Pak1^{−/−}$
Figure 23- Krox20Cre;Nf1\textsuperscript{flp/} mice reconstituted with Nf1\textsuperscript{+/};Pak1\textsuperscript{-/-} mice develop enlarged sciatic nerve dorsal root ganglia. Krox20Cre;Nf1\textsuperscript{flp/} mice were sacrificed 12-15 months after transplantation with Nf1\textsuperscript{+/} or Nf1\textsuperscript{+/};Pak1\textsuperscript{-/-} bone marrow and the spinal cord and nerve roots of each animal were dissected. The dorsal root ganglia dimensions were obtained by measurement with calipers and volume was determined by using the formula (0.52 x (width)\textsuperscript{2} x (length)) to approximate spheroidal volume. Values represent the mean of 6 recipients of Nf1\textsuperscript{+/} marrow and 4 recipients of Nf1\textsuperscript{+/};Pak1\textsuperscript{-/-} marrow, and error bars represent the standard error of the mean. No significant difference between the means of the two genotypes was found using Student’s unpaired T test.
Figure 24

Normal  \[ N\text{f}1^{+/\sim} \]  \[ N\text{f}1^{+/\sim};Pak1^{-/-} \]

Bone marrow genotype
**Figure 24** *Krox20Cre;Nf1\textsuperscript{flox/-} mice reconstituted with \textit{Nf1}\textsuperscript{+/+};\textit{Pak1}\textsuperscript{-/-} bone marrow develop histologically identifiable plexiform neurofibromas.* Representative hematoxylin and eosin (H&E) stained sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1\textsuperscript{flox/-}* mice transplanted with either \textit{Nf1}\textsuperscript{+/-} marrow or \textit{Nf1}\textsuperscript{+/-};\textit{Pak1}\textsuperscript{-/-} marrow. Blood vessels are identified by red arrows. Genotypes of donor bone marrow are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.
Figure 25

Normal  \( Nf1^{+/-} \)  \( Nf1^{+/-}; Pak1^{-/-} \)

Bone marrow genotype
Figure 25- *Krox20Cre;Nf1^{floxed}* mice reconstituted with *Nf1^{+/+};Pak1^{−/−}* bone marrow have collagen deposition characteristic of plexiform neurofibromas. Representative sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1^{floxed}* mice transplanted with either *Nf1^{+/−}* marrow or *Nf1^{+/−};Pak1^{−/−}* marrow were stained with Masson’s trichrome to identify collagen content. Collagen is identified by bright blue staining. Genotypes of donor bone marrow are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.
Figure 26a

No Tumor  \hspace{1cm} Nsf1^+/^-  \hspace{1cm} Nsf1^+/^-;Pak1^-/-

Bone marrow genotype
Figure 26b

Mast cells/HPF

Bone marrow genotype

Nfl+/-

Nfl+/-;Pak1-/-
Figure 26- *Krox20Cre;Nf1^{flx/-}* mice reconstituted with *Nf1^{+/+};Pak1^{-/-}* bone marrow have plexiform neurofibromas infiltrated with numerous inflammatory mast cells. 

A) Representative sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1^{flx/-}* mice transplanted with either *Nf1^{+/+}* marrow or *Nf1^{+/+};Pak1^{-/-}* marrow were stained with Alcian blue to identify mast cell numbers. Mast cells are identified by red arrows. Genotypes of donor bone marrow are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification. 

B) Number of mast cells present in Alcian blue sections from 4 animals per genotype were quantitated by counting mast cells per high power field. Values represent the mean and the error bars represent the standard error of the mean. No significant difference between the means of the two genotypes was found using Student’s unpaired T test.
Nf1<sup>+/–</sup>Pak1<sup>+/–</sup> mice generated Krox20Cre;Nf1<sup>flox/–</sup>Pak1<sup>+/–</sup> progeny in the F2 generation. These Krox20Cre;Nf1<sup>flox/–</sup>Pak1<sup>+/–</sup> mice were followed for 12-15 months with Krox20Cre;Nf1<sup>flox/–</sup> mice as positive controls to assess plexiform neurofibroma development. After 12 months, the survival of Krox20Cre;Nf1<sup>flox/–</sup>Pak1<sup>+/–</sup> mice was equivalent to the Krox20Cre;Nf1<sup>flox/–</sup> mice (~50% survival for both genotypes).

Dissection of the spinal cord and proximal spinal nerves revealed enlargement of the dorsal root ganglia and spinal nerve roots in Krox20Cre;Nf1<sup>flox/–</sup>Pak1<sup>+/–</sup> mice (Figure 27). Volumetric analysis of these dorsal root ganglia showed no significant changes in the volume of the dorsal root ganglia of the sciatic nerve between Krox20Cre;Nf1<sup>flox/–</sup>Pak1<sup>+/–</sup> mice and Krox20Cre;Nf1<sup>flox/–</sup> mice (Figure 27).

Krox20Cre;Nf1<sup>flox/–</sup>Pak1<sup>+/–</sup> mice displayed histological signs of neurofibroma formation as evidenced by disruptions in nerve root architecture (Figure 28), increased angiogenesis (Figure 28, red arrows), high amounts of collagen deposition (Figure 29), and the infiltration of mast cells (Figure 30a, red arrows). No significant differences in mast cell numbers within the neurofibroma were found (Figure 30b).

Table 1 details the results of plexiform neurofibroma experiments performed by our group and colleagues and lists the genotypes of the relevant cell lineages in each set of trials. The results of the experiments described in detail within this study demonstrate that genetic disruption of Pak1 in the Krox20Cre;Nf1<sup>flox/–</sup> plexiform neurofibroma tumor model is insufficient for preventing tumor formation in vivo.
Figure 27

![Bar chart showing volume comparisons between different genotypes. The x-axis represents different genotypes: Krox20Cre;Nf1^{lox/lox} and Krox20Cre;Nf1^{lox/lox};Pak1^{-/-}. The y-axis represents volume in mm^3. The chart indicates a higher volume for Krox20Cre;Nf1^{lox/lox} compared to Krox20Cre;Nf1^{lox/lox};Pak1^{-/-}.](image-url)
Figure 27- *Krox20Cre;Nf1^{floxed};Pak1^{-/-}* mice develop enlarged sciatic nerve dorsal root ganglia. *Krox20Cre;Nf1^{floxed};Pak1^{-/-} and Krox20Cre;Nf1^{floxed}* mice were sacrificed after 12-15 months and the spinal cord and nerve roots of each animal were dissected. The dorsal root ganglia dimensions were obtained by measurement with calipers and volume was determined by using the formula \((0.52 \times \text{width})^2 \times \text{length})\) to approximate spheroidal volume. Values represent the mean of 15 animals per genotype and error bars represent the standard error of the mean. No significant difference between the means of the two genotypes was found using Student’s unpaired T test.
Figure 28

No Tumor

Krox20Cre; Nf1<sup>flc</sup><sup>−/−</sup>

Krox20Cre; Nf1<sup>flc</sup><sup>−/−</sup>; Pak1<sup>−/−</sup>
Figure 28- *Krox20Cre;Nf1^{floox}/;Pak1^{−/−}* mice develop histologically identifiable plexiform neurofibromas. Representative hematoxylin and eosin (H&E) stained sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1^{floox}/;Pak1^{−/−}* and *Krox20Cre;Nf1^{floox}/* mice. Blood vessels are identified by red arrows. Genotypes of each group are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.
Figure 29

No Tumor  \hspace{1cm}  Krox20Cre; Nf1flex+  \hspace{1cm}  Krox20Cre; Nf1flex-; Pak1-
Figure 29- *Krox20Cre;Nf1^{flax/ };Pak1^{-/}* mice have collagen deposition characteristic of plexiform neurofibromas. Representative sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1^{flax/ };Pak1^{-/}* mice and *Krox20Cre;Nf1^{flax/}* mice were stained with Masson’s trichrome to identify collagen content. Collagen is identified by bright blue staining. Genotypes of each group are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification.
Figure 30a

No Tumor  Krox20Cre;Nf1<sup>fl</sup><sup>x</sup>-  Krox20Cre;Nf1<sup>fl</sup><sup>x</sup>-<sup>+:Pak1</sup>
Figure 30b

![Bar graph showing mast cells/HPF for Krox20Cre;Nf1^lox/+ and Krox20Cre;Nf1^lox/+;Pak1^-/- genotypes.](image-url)
**Figure 30-** *Krox20Cre;Nf1*\textsuperscript{flco}/;*Pak1*\textsuperscript{-/-} mice have plexiform neurofibromas infiltrated with numerous inflammatory mast cells. A) Representative sections of dorsal root ganglia and proximal peripheral nerves from *Krox20Cre;Nf1*\textsuperscript{flco}/;*Pak1*\textsuperscript{-/-} mice and *Krox20Cre;Nf1*\textsuperscript{flco}/ mice were stained with Alcian blue to identify mast cell numbers. Mast cells are identified by red arrows. Genotypes of each group are indicated, along with a representative section of normal nerve root. Photos were taken with a light microscope under 200x magnification. B) Number of mast cells present in Alcian blue sections from 4 animals per genotype were quantitated by counting mast cells per high power field. Values represent the mean and the error bars represent the standard error of the mean. No significant difference between the means of the two genotypes was found using Student’s unpaired T test.
<table>
<thead>
<tr>
<th>Recipient</th>
<th>Donor</th>
<th>Schwann Cells</th>
<th>Mast/ Hematopoietic cells</th>
<th>Fibroblasts</th>
<th>Neurofibromas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krox20Cre; Nfl1flox/flox</td>
<td>n/a</td>
<td>Nfl1-/</td>
<td>Nfl1+/</td>
<td>Nfl1+/</td>
<td>No</td>
</tr>
<tr>
<td>Krox20Cre; Nfl1flox/-</td>
<td>n/a</td>
<td>Nfl1-/</td>
<td>Nfl1+/</td>
<td>Nfl1+/</td>
<td>Yes</td>
</tr>
<tr>
<td>Krox20Cre; Nfl1flox/flox</td>
<td>Nfl1/+/</td>
<td>Nfl1-/</td>
<td>Nfl1+/</td>
<td>Nfl1+/</td>
<td>Yes</td>
</tr>
<tr>
<td>Krox20Cre; Nfl1flox/-</td>
<td>Nfl1/+/</td>
<td>Nfl1-/</td>
<td>Nfl1+/</td>
<td>Nfl1+/</td>
<td>No</td>
</tr>
<tr>
<td>Krox20Cre; Nfl1flox/flox</td>
<td>Nfl1/++;Pak1/-</td>
<td>Nfl1-/</td>
<td>Nfl1/++;Pak1/-</td>
<td>Nfl1/++;Pak1/-</td>
<td>Yes</td>
</tr>
<tr>
<td>Krox20Cre; Nfl1flox/-</td>
<td>Nfl1/++;Pak1/-</td>
<td>Nfl1-/</td>
<td>Nfl1/++;Pak1/-</td>
<td>Nfl1/++;Pak1/-</td>
<td>Yes</td>
</tr>
<tr>
<td>Krox20Cre; Nfl1flox/-;Pak1/-</td>
<td>n/a</td>
<td>Nfl1/++;Pak1/-</td>
<td>Nfl1/++;Pak1/-</td>
<td>Nfl1/++;Pak1/-</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Table 1- Results of plexiform neurofibroma formation studies using the

*Krox20Cre;Nf1^flox* conditional knockout animal model.
ROLE OF Pak1 IN MEDIATING PDGF-BB AND TGF-β DEPENDENT FUNCTIONS IN FIBROBLASTS

PDGF-BB mediated fibroblast proliferation is Pak1 dependent

Work by Rhee and Grinnell demonstrated that human fibroblasts treated with siRNA to Pak1 had disruptions in their ability to form cell ruffles and dendritic extensions of the cytoplasm in response to PDGF-BB \(^{186}\). Since fibroblast activity and collagen secretion is important to the pathogenesis of plexiform neurofibromas, we examined whether a role for Pak1 existed in regulating various PDGF-BB dependent functions. First, we stimulated wild type and Pak1\(^{-/-}\) fibroblasts with 50ng/mL of PDGF-BB for 36 hours and carried out \(^{[3H]}\) thymidine incorporation assays to evaluate proliferation. Figure 31 shows that disruption of Pak1 causes significant decreases in fibroblast proliferation. PDGF-BB activation of Erk is critical to its role in stimulating proliferation \(^{187}\), and we and others have shown that Pak1 is necessary for activation of Erk. Therefore, we stimulated fibroblasts with 50ng/mL of PDGF-BB and assayed for activated Erk1/2 by using phospho-specific antibodies after Western blotting. Pak1\(^{-/-}\) fibroblasts consistently display decreased activation of Erk1/2 (Figure 32) suggesting a molecular mechanism for the findings of Figure 31.
Figure 31

Fold increase over baseline

+/-

Pak1-/-
Figure 31- *Pak1*−/− fibroblasts have reduced proliferation following PDGF-BB stimulation. Approximately 2x10^4 fibroblasts were plated and starved for 24 hours before stimulation with 50ng/mL of PDGF-BB. After 24 hours of stimulation at 37°C, [3H]thymidine was added for 6 hours and its incorporation was measured. Values represent the mean of 3 independent experiments performed with six replicates each and the error bars represent the standard error of the mean. * indicates p<0.05 compared to WT control using Student’s unpaired T test.
Figure 32

Random Units

+/+

Pak 1 -/-

Phospho-ERK

PDGF (min) 0 2 5 15 30

Total ERK

0 2 5 15 30
Figure 32- Loss of Pak1 reduces Erk activation following PDGF-BB stimulation in fibroblasts. Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of PDGF-BB, and cell lysates isolated at time points indicated following stimulation. 100µg of protein were used for each time point. Levels of active Erk1/2 were determined by immunoblotting using phospho-specific antibodies. Levels of total Erk1/2 are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments.
Loss of Pak1 does not affect TGF-β induced fibroblast proliferation

Similar to PDGF-BB, TGF-β is a growth factor that stimulates multiple responses from fibroblasts. TGF-β is a potent modulator of fibroblast proliferation and is known to be released at high concentrations by mast cells in the neurofibroma microenvironment. Therefore, we examined whether Pak1 deficient fibroblasts had reduced proliferation after TGF-β stimulation. Unlike stimulation with PDGF-BB, Pak1−/− fibroblasts had no statistically significant changes in [3H]thymidine incorporation after 36 hours of incubation with 2ng/mL TGF-β (Figure 33). This was accompanied by immunoblots detailing no change in activated Erk levels after TGF-β stimulation (Figure 34). Together, these results indicate that Pak1 is important for MAPK activation and proliferation of fibroblast after stimulation with PDGF-BB, but not TGF-β.

Pak1 deficient fibroblasts have reduced migration following PDGF-BB stimulation

Early work on Pak1 in fibroblast cell lines indicated that Pak1 regulated actin organization and content following PDGF-BB stimulation. More recent work has implied a role for Pak1 in regulating fibroblast migration in response to PDGF-BB. Based on these reports, we used primary Pak1−/− fibroblasts to investigate how loss of Pak1 could affect PDGF-BB ability to induce migration and signal to the cytoskeleton. We used a wound-healing assay as an assessment of fibroblast migration following PDGF-BB treatment. These experiments revealed a 2.5 fold increase in the migration of wild type fibroblasts as compared to Pak1−/− cells (Figure 35). Representative
Figure 33

![Bar chart showing fold increase over baseline for +/+ and Pak1-/- genotypes. The bar for +/+ is significantly higher than that for Pak1-/-, indicating a greater fold increase in the wild-type condition.]
Figure 33- Loss of Pak1 does not significantly affect fibroblast proliferation following TGF-β stimulation. Approximately 2x10^4 fibroblasts were plated and starved for 24 hours before stimulation with 2ng/mL of TGF-β. After 24 hours of stimulation at 37°, [3H]thymidine was added for 6 hours and its incorporation was measured. Values represent the mean of 3 independent experiments performed with six replicates each and the error bars represent the standard error of the mean. No significant difference between the means of the two genotypes was found using Student’s unpaired T test.
Figure 34

<table>
<thead>
<tr>
<th>TGF (min)</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>30</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phospho-ERK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total ERK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

+/-+  |  Pak 1 +/- |
Figure 34- *Pak1*⁺ fibroblasts have normal Erk activation after stimulation with TGF-β. Fibroblasts were serum starved for 48 hours, stimulated with 2ng/mL of TGF-β, and cell lysates isolated at time points indicated following stimulation. 100µg of protein were used for each time point. Levels of active Erk1/2 were determined by immunoblotting using phospho-specific antibodies. Levels of total Erk1/2 are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments.
photomicrographs of crystal violet stained wild type or Pak1−/− fibroblasts that migrated into the wound in response to 18 hours of 50ng/mL PDGF-BB stimulation is shown in Figure 35.

Disruptions of PDGF-BB mediated activation of the actin cytoskeleton and associated signaling networks are found in Pak1−/− fibroblasts

Since we found Pak1−/− fibroblasts to have reduced migration, and numerous reports describe Pak1 altering migration via the actin cytoskeleton, we investigated the activation of important downstream targets of Pak1 that regulate actin, including filamin A and cofilin. First activation of filamin A was assessed. Phosphorylation of filamin A at Ser2152 increases its ability to bind actin and reorganize the cytoskeleton. We show that Pak1−/− fibroblasts have decreased Ser2152 phosphorylation of filamin A after PDGF-BB stimulation (Figure 36). Additionally, we examined the phosphorylation status of cofilin, an actin binding protein that, in its dephosphorylated state, leads to depolymerization of actin filaments. Figure 37 shows that fibroblasts that lack Pak1 have decreased phospho-cofilin, indicating an increase in the actin disrupting ability of cofilin. Taken together, these results implied that the actin cytoskeleton was likely to be deregulated in Pak1−/− fibroblasts. To visualize the actin networks in PDGF-BB stimulated fibroblasts, cells grown on coverslips were used in wound healing assays and after 5 hours were stained with phalloidin to stain filamentous actin. Representative micrographs taken from confocal analysis of these cells indicates that wild type fibroblasts stimulated with PDGF-BB have increased invasion of the wound compared
Figure 35- *Pak1*⁺ fibroblasts have diminished migration in response to PDGF-BB.

Quiescent, mitotically inactivated monolayers of fibroblasts were scratched with a pipette tip prior to stimulation with 50ng/mL of PDGF-BB. After 12 hours incubation, the cells were fixed and stained with crystal violet solution and the number of cells that invaded the wound were counted. Photos were taken with a light microscope under 100x magnification. Values represent the mean of 3 independent experiments performed in triplicate and the error bars represent the standard error of the mean. * indicates p<0.05 compared to WT control using Student’s unpaired T test.
Figure 36

Bar chart showing arbitrary density units for Phospho-FilaminA and β-actin for (+/+) and Pak 1 -/- conditions.

<table>
<thead>
<tr>
<th>PDGF-BB (min)</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phospho-FilaminA (+/+)</td>
<td><img src="image1.png" alt="Image" /></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phospho-FilaminA Pak 1 -/-</td>
<td><img src="image2.png" alt="Image" /></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin (+/+)</td>
<td><img src="image3.png" alt="Image" /></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin Pak 1 -/-</td>
<td><img src="image4.png" alt="Image" /></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 36- *Pak1* loss reduces activation of Filamin-A after PDGF-BB stimulation.

Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of PDGF-BB, and cell lysates isolated at time points indicated following stimulation. 100µg of protein were used for each time point. Levels of active Filamin-A were determined by immunoblotting using phospho-specific antibodies. Levels of total β-actin are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments.
Figure 37

Arbitrary Density Units

+/-

Pak 1 +/-

Phospho-Cofilin

PDGF-BB (min) 0 5 10 15 30

Total Cofilin

PDGF-BB (min) 0 5 10 15 30
Figure 37- *Pak1* loss results in reduced inactivation of Cofilin following stimulation by PDGF-BB. Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of PDGF-BB, and cell lysates isolated at time points indicated following stimulation.

100µg of protein were used for each time point. Levels of inactive cofilin were determined by immunoblotting using phospho-specific antibodies. Levels of total cofilin are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments.
Figure 38- *Pak1*−/− fibroblasts have disruptions in the organization of the F-actin cytoskeleton after PDGF-BB stimulation. Quiescent, mitotically inactivated monolayers of fibroblasts were scratched with a pipette tip prior to stimulation with 50ng/mL of PDGF-BB. After 5 hours incubation, the cells were fixed and stained with phalloidin and DAPI to visualize F-actin and nuclei, respectively. Low power micrographs in A-D) were taken with the Zeiss UV LSM-510 confocal microscope system. Green=phalloidin stain, blue=DAPI nuclear stain. Original magnification x100. E-F) are high power views of similar fields of cells. Original magnification x400.
to Pak1−/− cells (Figure 38b and 38d). Furthermore, wild type fibroblasts have qualitatively more F-actin in the cytoplasm of cells invading the wound than the Pak−/− cells, as evidenced by the high power micrographs shown in Figure 38 f and h, respectively. As a group, the results of these experiments indicate that loss of Pak1 results in decreased phosphorylation of filamin A and cofilin, leading to disruptions of the actin cytoskeleton that impair normal migration in response to PDGF-BB.

**Loss of Pak1 decreases TGF-β dependent fibroblast migration**

TGF-β mediated wound invasion is an important step in many pathological processes, including tumor formation. To determine if Pak1 signaling downstream of TGF-β was involved in the regulation of fibroblast migration, wound healing assays using 2ng/mL of TGF-β for stimulation were performed. After 24 hours of stimulation, the Pak1−/− fibroblasts displayed a significant reduction in wound invasion compared to wild type (Figure 39). Similar to the results found with PDGF-BB, Pak1−/− fibroblasts have impaired migration ability.

**TGF-β stimulated fibroblasts have decreased activation of filamin A and disrupted actin cytoskeletal networks**

Since Pak1−/− fibroblasts had comparable deficits in migration in response to both PDGF-BB and TGF-β stimulation, we were interested if TGF-β induced similar disruption of actin signaling networks found in PDGF-BB stimulated Pak1 null cells.
Analogous to PDGF-BB stimulated fibroblasts, loss of Pak1 results in impaired phosphorylation of filamin A at Ser 2152 (Figure 40). Interestingly, in response to TGF-β, coflin phosphorylation remained intact in Pak1−/− cells (Figure 41). However, confocal analysis of phalloidin stained fibroblasts stimulated with 2ng/mL of TGF-β for 5 hours showed decreased amounts of higher level actin bundle organization in wound invading Pak1−/− cells (Figure 42 h, red arrow) compared to wild type cells. These experiments point toward a potential Pak1 mediated signaling pathway where Filamin A, but not coflin, is an important regulator of TGF-β mediated actin organization and fibroblast migration.

Pak1−/− fibroblasts have reduced collagen synthesis in vitro in response to TGF-β

Interstitial collagen secretion is one of the primary functions of fibroblasts and is associated with numerous disease processes, including plexiform neurofibroma formation. Since both PDGF-BB and TGF-β are known profibrotic cytokines and are released in large amounts by mast cells at the site of plexiform neurofibroma formation, we investigated if loss of Pak1−/− would alter the ability of fibroblasts to secrete collagen following stimulation with either growth factor. Using the Sircol™ collagen assay system, we evaluated the supernatants from confluent cultures of fibroblasts stimulated for 48 hours with either 50ng/mL PDGF-BB or 2ng/mL TGF-β for collagen production. Although PDGF-BB stimulated Pak1−/− fibroblasts had statistically similar amounts of collagen secretion as wild type cells; TGF-β stimulation led to decreased collagen production in Pak1 null cells (Figure 43). This experiment supports a
Figure 39

![Graph showing the number of cells invaded in different conditions.](image)

- +/-
- Pak1-/-

![Images of tissue sections showing differences in cell invasion.](images)
**Figure 39-** *Pak1*−/− fibroblasts have diminished migration in response to TGF-β.

Quiescent, mitotically inactivated monolayers of fibroblasts were scratched with a pipette tip prior to stimulation with 2ng/mL of TGF-β. After 24 hours incubation, the cells were fixed and stained with crystal violet solution and the number of cells that invaded the would were counted. Photos were taken with a light microscope under 100x magnification. Values represent the mean of 3 independent experiments performed in triplicate and the error bars represent the standard error of the mean. * indicates p<0.05 compared to WT control using Student’s unpaired T test.
**Figure 40- Pak1 loss reduces activation of Filamin-A after TGF-β stimulation.**

Fibroblasts were serum starved for 48 hours, stimulated with 2ng/mL of TGF-β, and cell lysates isolated at time points indicated following stimulation. 100µg of protein were used for each time point. Levels of active Filamin-A were determined by immunoblotting using phospho-specific antibodies. Levels of total β-actin are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments.
Figure 41- *Pak1* loss does not significantly affect phosphorylation of Cofilin following stimulation by TGF-β. Fibroblasts were serum starved for 48 hours, stimulated with 50ng/mL of TGF-β, and cell lysates isolated at time points indicated following stimulation. 100µg of protein were used for each time point. Levels of inactive cofilin were determined by immunoblotting using phospho-specific antibodies. Levels of β-actin are shown as loading controls. Western blot of the results is shown and is a representative of three independent experiments.
Figure 42- *Pak1*−/− fibroblasts have disruptions in the organization of the F-actin cytoskeleton after TGF-β stimulation. Quiescent, mitotically inactivated monolayers of fibroblasts were scratched with a pipette tip prior to stimulation with 2ng/mL of TGF-β. After 5 hours incubation, the cells were fixed and stained with phalloidin and DAPI to visualize F-actin and nuclei, respectively. Low power micrographs in A-D) were taken with the Zeiss UV LSM-510 confocal microscope system. Green=phalloidin stain, blue=DAPI nuclear stain. Original magnification x100. E-F) are high power views of similar fields of cells. Original magnification x400.
Figure 43

The bar chart illustrates the comparison of collagen (µg/mL) production in PDGF-BB and TGF-β conditions. The black bars represent the +/+ group, while the white bars indicate the PakI-/- group. A significant difference is marked with an asterisk (*) for the TGF-β condition.
Figure 43- Loss of Pak1 reduces collagen production after TGF-β stimulation.

Confluent monolayers of fibroblasts were stimulated with 50ng/mL of PDGF-BB or 2ng/mL of TGF-β for 48 hours at 37°C. Collagen levels in the supernatant were measured using the Sircol™ dye reagent and OD levels assessed using a microplate reader. Values represent the mean of 3 independent experiments performed in triplicate and the error bars represent the standard error of the mean. * indicates p<0.05 compared to WT using Student’s unpaired T test.
role for Pak1 in regulating collagen production from fibroblasts in response to TGF-β.

Reduced survival of Pak1 null fibroblasts in response to TGF-β and PDGF-BB

Due to the fact that Pak1 is associated with anti-apoptotic actions in other cell types\textsuperscript{143,184,185}, we were interested to see if genetic disruption of Pak1 in fibroblasts would affect their survival in response to PDGF-BB or TGF-β. Confluent fibroblasts were serum starved for 24 hours before being treated with 10% fetal calf serum, 50ng/mL PDGF-BB, or 2ng/mL TGF-β. Cells were fixed and subjected to a TUNEL assay and analyzed for survival using fluorescence cytometry. Cells that were left in 10% fetal calf serum showed no difference in apoptosis (as determined by TUNEL positivity) between the genotypes (Figure 44a). However, Pak1\textsuperscript{+/−} cells have small but significant increases in apoptosis compared to wild type when exposed to both PDGF-BB and TGF-β (Figure 44c and d). This finding is in contrast to the results of Figure 16, which show that mast cell survival in response to SCF is not affected by loss of Pak1. Taken together, these studies demonstrate that Pak1 anti-apoptotic effects are cell type and stimulus dependent.

Loss of Pak1 inhibits fibroblast recruitment in vivo

In order to determine whether Pak1 regulates the migration of fibroblasts in response to growth factors in vivo, we performed ECM matrix invasion assays with wild type and Pak1\textsuperscript{−/−} mice. Our lab has previously established that implantation of Cultrex™
Figure 44

a. 

Percent TUNEL positive

+/+ Pak1−/−

10% Serum, 72h

b. 

Percent TUNEL positive

+/+ Pak1−/−

0% Serum, 24h

c. 

Percent TUNEL positive

+/+ Pak1−/−

50ng/mL PDGF-BB, 72h

d. 

Percent TUNEL positive

+/+ Pak1−/−

1ng/mL TGF-β, 72h
Figure 44- Pak1−/− fibroblasts have decreased survival after PDGF-BB and TGF-β exposure. Confluent monolayers of fibroblasts were starved for 24 hour prior to stimulation with 50ng/mL of PDGF-BB or 2ng/mL of TGF-β in media lacking serum. After 72 hours, survival was assessed by TUNEL assay according to the manufacturers instructions. Values represent the mean of 6 independent experiments performed in triplicate and the error bars represent the standard error of the mean. * indicates p<0.05 compared to WT using Student’s unpaired T test.
basement membrane extract with PDGF-BB or TGF-β into the groin of mice induces fibroblast invasion from the surrounding tissue\textsuperscript{71}. Seven days after Cultrex$^{\text{TM}}$ implantation, the plugs were removed, sectioned, and stained with hematoxylin and eosin (H&E) to visualize the extent of fibroblast migration. Figure 45a displays the results taken from mice implanted with PDGF-BB or vehicle, showing a significant reduction in fibroblast recruitment in Pak1$^{-/-}$ mice. Representative sections that display the invading fibroblasts are also shown (Figure 45b-d). In parallel experiments using plugs containing TGF-β, we found similar results, with a significant decrease in invading fibroblasts from Pak1$^{-/-}$ mice (Figure 46a). The amount of fibroblast infiltration can be observed in the representative plug sections shown in Figure 46b-d.

**Genetic disruption of Pak1 reduces the severity of bleomycin induced lung fibrosis**

Harrison and Lezo have described an \textit{in vivo} experimental murine model to stimulate pathologic fibrosis in lungs using bleomycin sulfate delivered from subcutaneously implanted micro-osmotic pumps\textsuperscript{172}. Bleomycin induces lung fibrosis by activating both the TGF-β\textsuperscript{189-191} as well as PDGF-BB\textsuperscript{192-194} pathways to stimulate fibroblast proliferation and collagen deposition. Inhibition of the PDGF-BB and TGF-β pathways via imatinib prevents bleomycin induced lung fibrosis in mice\textsuperscript{193}.

Based on these previous reports and on our \textit{in vitro} findings implicating Pak1 as an important downstream mediator of PDGF-BB and TGF-β signals in fibroblasts, we used bleomycin to induce lung fibrosis in wild type and Pak1$^{-/-}$ mice. After 28 days of bleomycin or PBS exposure, lungs were harvested and either fixed for histological
sections or used for collagen content assays. Figure 47a-d displays representative
hematoxylin and eosin (H&E) stained slides taken from each genotype, revealing that
Figure 45- Pak1⁻/⁻ mice have decreased PDGF-BB mediated fibroblast invasion into Cultrex™ plugs. A) Quantitative scoring of fibroblast invasion into Cultrex™ plugs containing PBS or 200ng/mL of PDGF-BB. Values represent the mean of five individual sections from 4 mice per genotype and error bars represent the standard error of the mean. * indicates p<0.05 compared to WT using Student’s unpaired T test. Also shown (B-E) are representative hematoxylin and eosin (H&E) stained sections from Cultrex plugs containing PDGF-BB or PBS.
Figure 46a

![Bar chart showing invasion of fibroblasts/HPF](chart.png)

- **+/+**
- **+/+**
- **Pak1⁻⁻**
- **Pak1⁻⁻**

- PBS
- TGF-β
- PBS
- TGF-β

*Statistical significance indicated by asterisk.*
Figure 46- *Pak1*<sup>−/−</sup> mice have decreased TGF-β mediated fibroblast invasion into Cultrex™ plugs. A) Quantitative scoring of fibroblast invasion into Cultrex™ plugs containing PBS or 10 ng/mL of TGF-β. Values represent the mean of five individual sections from 4 mice per genotype and error bars represent the standard error of the mean. * indicates *p* < 0.05 compared to WT using Student’s unpaired T test. Also shown (B-E) are representative hematoxylin and eosin (H&E) stained sections from Cultrex plugs containing TGF-β.
exposure to bleomycin induces dramatic fibrosis compared to PBS treated animals.

Using a quantitative measurement of lung fibrosis developed by Ashcroft, we determined that Pak1^{-/-} mice had a modest (~20%), but significant (p<.0001) reduction in fibrosis severity compared to wild type animals (Figure 47e). Correspondingly, using the Sircol™ assay system, we found that lungs from Pak1^{-/-} mice had a significant decrease in collagen content (Figure 47f), similar in degree to the change in fibrosis severity. Collectively, the results of Figure 47 indicate a role for Pak1 in the pathophysiology of bleomycin mediated lung fibrosis disease model.
Figure 47

a. 

+/+ PBS

b. 

+/+ Bleomycin

c. 

Pak1/- PBS

d. 

Pak1/- Bleomycin
Figure 47e

![Bar chart showing Ashcroft Score for different groups: PBS, Bleomycin, Pak1+/+, and Pak1-/-.

The chart indicates a significant difference (*) between Pak1-/- and the other groups.](image-url)
Figure 47f

Bar graph showing collagen pg/mL for different conditions:
- +++
- ++
- Pak1-/-
- Pak1-/-

Conditions:
- PBS
- Bleomycin

Bars in black represent Bleomycin treatment, while bars in white represent PBS treatment.
**Figure 47- Loss of Pak1 reduces bleomycin induced lung fibrosis.**

**A-D)** Representative hematoxylin and eosin (H&E) stained sections from lungs treated with either PBS or 125mg/kg/day of bleomycin sulfate for 28 days. **E)** Extent of lung fibrosis as measured by the Ashcroft scoring system. Fields from 8 mice per genotype that received either PBS or bleomycin sulfate were scored in a blinded fashion by 4 independent researchers. Values represent the mean score of 8 animals per condition and error bars represent the standard error of the mean. * indicates p<0.05 compared to WT using Student’s unpaired T test. **F)** After 28 days of drug exposure, lungs were removed, minced and collagen extracted with pepsin and acetic acid. The amount of collagen present in each lung was assessed by Sircol™ dye assay. Values represent the mean amount of collagen from lungs of 4 animals per condition performed in triplicate and error bars represent the standard error of the mean. * indicates p<0.05 compared to WT using Student’s unpaired T test.
DISCUSSION

In the history of neurofibromatosis type I, identification of the \textit{NF1} gene and the GTPase activating ability of its gene product neurofibromin\textsuperscript{24} provided the keystone for future research into the molecular alterations responsible for the pathophysiology of this disease. Based on the autosomal dominant mode of disease inheritance and the genetic background of tissue samples taken from patient tumors\textsuperscript{195}, neurofibromin has been commonly classified as a tumor suppressor protein. However, work from our lab\textsuperscript{59,62,75} and others\textsuperscript{30,196,197} has demonstrated that in mouse models, single copy of loss of \textit{Nf1} leads to tumor promoting gains-in-function, in opposition to Knudson’s “two-hit” hypothesis\textsuperscript{198}. Clinical observations from NF1 patients such as patient-to-patient variability in tumor number and the overall low risk of malignant transformation in neurofibromas support these findings of gene dosage effects. Therefore, it is critical for researchers in the neurofibromatosis field to uncover the molecular nature of \textit{Nf1} haploinsufficient phenotypes in order to completely under the disease’s progression.

Thus, a primary objective of this thesis was to examine whether a candidate protein, Pak1, functioned in regulating intracellular signal transduction in NF1 relevant pathways and if so, whether Pak1 played a role in neurofibroma tumorigenesis. To this end, a genetically engineered \textit{Pak1} knockout mouse was employed in various intercrosses to assess molecular, cellular, and disease phenotypes. Loss of \textit{Pak1} corrected multiple \textit{Nf1} haploinsufficient gain-in-function phenotypes in mast cells and Pak1 was demonstrated to be an important regulator of fibroblast function in response to two significant growth factors. However, using genetic intercrosses as well as
hematopoietic cell transplantation in an *in vivo* animal model that closely recapitulates human disease, we established that *Pak1* loss is insufficient for prevention of neurofibroma formation.

**Role of *Pak1* in regulating c-kit mediated *Nf1*+/− mast cell function**

Mast cells carry out their functions by migrating toward signals emanating from local microenvironments, followed by local proliferation, and subsequently releasing inflammatory mediators (including proteases). The NF1 disease model has well known associations between Ras related gains-in-function in mast cells and the pathologic complications this disorder 59,63,199,200. These cellular phenotypes and increased Ras activity have also been observed in NF1 patient samples (S. Chen, F.C. Yang, D.W. Clapp, unpublished results).

Bone marrow mononuclear cells from *Pak1*−/− animals develop *in vitro* into mature mast cells normally, as measured by the expression of c-kit and FcεRI surface markers (Figure 6). Additionally, haploinsufficiency at *Nf1* also did not affect c-kit or FcεRI expression levels. Therefore the results shown in experiments utilizing mast cells were not the consequence of alterations in the number of ligand binding sites for SCF and instead due to changes in intracellular signaling.

Here we use pharmacologic, genetic, and biochemical approaches to demonstrate that the hyperproliferation of *Nf1*+/− mast cells in response to SCF is the result of Pak1 signaling to the MEK/Erk pathway. Although multiple studies link Pak1 to MAPK signaling in overexpression systems 131-133,160,201,202, in this report we establish for the first
time in primary cells using a knockout model that Pak1 loss leads to decreased activation of MEK and Erk. Importantly, subcutaneous insertion of microosmotic pumps continuously releasing SCF in Nf1+/--;Pak1−/− mice corrected the increased accumulation of mast cells in the dermis seen in Nf1+/− mice to wild type levels, correlating our in vivo results in a physiologically relevant system (Figure 17a) the mechanisms identified in vitro (Figure 7).

Furthermore, we also demonstrate that the increased release of preformed mediators associated with Nf1 haploinsufficiency seen in vitro is corrected when Pak1 is genetically disrupted. Interestingly, Pak1−/− mast cells do not have significant decreases in degranulation compared to wild type cells in response to SCF and IgE stimulation combined (Figure 14), but do have impaired degranulation in response to IgE stimulation alone (Figure 15). SCF stimulation could preferentially activate the Mek/Erk pathway, which we show to independent of Pak1 with regards to degranulation (Figure 15), to compensate for the decreased IgE dependent signals (J.D. Allen, D.W. Clapp, unpublished results) seen in Pak1−/− cells. Importantly, the amount of mast cell degranulation found in Nf1+/--;Pak1−/− mice in vivo is significantly reduced compared to Nf1+/− mice (Figure 17b).

Interestingly, although Nf1+/− mast cells have prolonged, Akt-mediated survival in response to SCF stimulation60, and Pak1 has been implicated as a potential anti-apoptotic mediator in some cell types, we found that loss of Pak1 had no significant effect on apoptosis or survival in mast cells (Figure 16). A potential explanation for this finding lies in the fact that Pak1’s anti-apoptotic actions have been reported to be the result of activation of Bad-1143-145. However, recent reports indicate that phosphorylation of Bad-
1 is not essential to hematopoietic cell survival responses resulting from PI-3K/Akt activation\textsuperscript{203}. Therefore our findings demonstrating the inconsequential role of Pak1 with regards to mast cell apoptosis correlate well with data disassociating Bad-1 from hematopoietic cell survival.

A basic tenet of mast cell biology is that the mast cell progenitors circulate in the peripheral blood after development in the bone marrow and must migrate from the bloodstream to peripheral tissues. \textit{Nf1} null Schwann cells (the tumorigenic cell of the neurofibroma) secrete a 6-7 fold higher concentration of SCF compared to wild type cells\textsuperscript{62}, which stimulates a pathologic gain in migration and proliferation of \textit{Nf1}\textsuperscript{+/-} but not WT mast cells \textit{in vitro}. Hyperactive \textit{Nf1}\textsuperscript{+/-} mast cells at the site of developing tumors could enhance the tumor forming ability of Schwann cells by means of their described role as potential “inducers” of neurofibroma pathogenesis via effects on the microenvironment\textsuperscript{63}. Work submitted from our group confirms this hypothesis after we observed that adoptive transfer of \textit{Nf1}\textsuperscript{+/-} mast cells, but not WT mast cells, into mice that have \textit{Nf1} conditionally deleted in the Schwann cell compartment (\textit{Krox20Cre};\textit{Nf1}\textsuperscript{fl/lox}) is necessary and sufficient to allow plexiform neurofibromas to develop \textit{in vivo} (F.C. Yang, D.A. Ingram and D.W. Clapp, manuscript submitted April 2008).

In figure 11 we demonstrate that loss of \textit{Pak1} reduces \textit{Nf1}\textsuperscript{+/-} mast cell migration by ~40\% in response to SCF and that this reduction is p38 dependent. Additionally, we present experimental evidence that SCF mediated increases in the F-actin cytoskeleton in \textit{Nf1}\textsuperscript{+/-} BMMCs are dependent on a Pak1-p38 pathway. \textit{Pak1}\textsuperscript{-/-} mast cells also have a significant decrease in mast cell migration compared to wild type cells, but to a lesser degree than seen between \textit{Nf1}\textsuperscript{+/-} and \textit{Nf1}\textsuperscript{+/-};\textit{Pak1}\textsuperscript{-/-} cells. This result is similar to the
characteristics of \( p85^\alpha^- \) and \( Rac2^- \) mast cells, as they are only modestly impaired in their SCF mediated migration but cause large decreases in haptotaxis in the context of \( Nf1 \) heterozygosity\(^{60} \). These findings indicate that the PI-3K/Rac2/Pak1 signaling axis, and by extension p38, are preferentially activated to stimulate the actin cytoskeleton and cell migration in the context of hyperactive Ras, and that under conditions of normal neurofibromin activity, other accessory pathways are also used to coordinate cell movement.

In \( Nf1^{+/} \) BMMCs, after stimulation by SCF, Ras becomes hyperactivated due to the lack of neurofibromin GAP activity. This leads to increased PI-3K/Rac activation\(^{59,61,204} \), and subsequent increases in Pak1 activity\(^{60} \). Hyperactivated Pak1 transmits mitogenic signals through selective activation of MEK and Erk and migratory signals through selective activation of p38 and the actin cytoskeleton. Therefore we propose that \( Pak1 \) acts as a significant “hub” of c-kit mediated hyperactive Ras signaling and that disruption of \( Pak1 \) can reduce the pathologic increases in proliferation and migration in \( Nf1 \) haploinsufficient BMMCs.

**\( Pak1 \) and plexiform neurofibroma formation**

Greater than 25% of NF1 patients have plexiform neurofibromas surrounding spinal nerve roots\(^{15} \), which can cause significant morbidity and premature death\(^{12} \). These tumors present major challenges to surgical treatment and no effective medical therapies for these tumors are available\(^{63} \). Further, plexiform neurofibromas have a propensity to transform into malignant peripheral nerve sheath tumors. Lack of existing
medical therapies has encouraged investigations into the cellular interactions in the neurofibroma microenvironment and molecular pathways regulating them in an attempt to identify potential pharmacologic targets for clinical use. Emerging evidence designating the mast cell as a key moderator of the pathophysiology at the site of neurofibroma development provides an attractive target for pharmacologic interventions.

If molecular therapeutics designed for correcting hyperactive pathways in Nf1+/− mast cells is developed, plexiform neurofibroma formation may be delayed or even prevented. For example, in recently submitted studies using the Krox20Cre;Nf1flx/− murine tumor model, we have effectively used the small molecule imatinib (which inhibits c-kit and other RTKs) to reduce plexiform neurofibroma mass and significantly extend survival. Currently, we are using this agent in a phase II clinical trial in pediatric NF1 patients with plexiform neurofibromas. Therefore, based on the in vitro data that implicated Pak1 as an important signaling molecule in disease related mast cell functions, we were eager to investigate whether loss of Pak1 would alter tumorigenesis using the Krox20Cre mouse model of NF1.

However, using both an adoptive transfer and genetic intercross approach, we were not able to prevent neurofibroma formation by targeted disruption of Pak1. This could be due to the influence of many factors. The findings described above that show corrections in gains of function in Nf1+/−;Pak1−/− mast cells were generated from experiments that used soluble SCF as the stimulus. However, in the actual tumor microenvironment, in addition to the soluble form, membrane bound forms of SCF exist, which has been described as a more potent activator of c-kit responses. In neurofibromatosis type 1 in general, and plexiform neurofibroma pathophysiology
specifically, the relative contribution of membrane bound SCF vis-à-vis soluble SCF is unknown.

The Sl" mutation deletes the transmembrane and cytoplasmic domains of SCF, and Sl/Sl" mice produce soluble but not membrane bound SCF. Sl/Sl" mice have macrocytic anemia and melanocyte deficits, and importantly, markedly reduced tissue mast cells. Since soluble and membrane bound SCF have similar affinity for c-kit, the reduced mast cell numbers found in Sl/Sl" mice imply that membrane bound SCF activates molecular signals downstream of c-kit that are essential for mast cell development and growth and are different than those activated by soluble SCF. The idea that soluble SCF cannot fully compensate for membrane bound SCF has been shown for other processes such as spermatogenesis, erythropoiesis, and in vivo melanocyte survival as well. Therefore, it is possible that membrane bound SCF at the site of developing neurofibromas might stimulate c-Kit to activate non-Pak1 dependent pathways to trigger mast cell tumor inducing phenotypes in Krox20Cre;Nf1\(^{\text{flax/flax}}\) or Krox20Cre;Nf1\(^{\text{flax/\text{--}}}\) mice that were reconstituted with Nf1\(^{+/--}\);Pak1\(^{--/--}\) bone marrow.

One notable finding from the adoptive transfer experiments was that although both Krox20Cre;Nf1\(^{\text{flax/flax}}\) and Krox20Cre;Nf1\(^{\text{flax/\text{--}}}\) mice reconstituted with Nf1\(^{+/--}\);Pak1\(^{--/--}\) bone marrow developed tumors, only Krox20Cre;Nf1\(^{\text{flax/flax}}\) recipients of Nf1\(^{+/--}\);Pak1\(^{--/--}\) bone marrow showed a decrease in mast cell numbers in the tumor compared to recipients of Nf1\(^{+/--}\) bone marrow (Figure 22b). Krox20Cre;Nf1\(^{\text{flax/\text{--}}}\) mice had similar numbers of invaded mast cells, regardless of marrow genotype (Figure 26b). One conclusion that could be drawn from this finding is that haploinsufficiency of the non-mast cell lineages of the tumor microenvironment produces more mast cell activating
factors compared to a wild type background. Given that fibroblasts are obligate producers of membrane bound SCF \(^{211,212}\), and that \(Nf1^{+/+}\) fibroblasts activate \(Nf1^{+/+}\) mast cells more intensely than wild type fibroblasts \(^{71}\); the findings of Figure 22b and 26b may be explained by increased production of membrane bound SCF in fibroblasts of \(Krox20\)Cre;\(Nf1^{flax}\) mice, stimulating \(Nf1^{+/+}\);\(Pak1^{+/+}\) mast cells to proliferate and release their granules in a \(Pak1\) independent fashion.

Another explanation for the results of the adoptive transfer neurofibroma experiments may lie in the unknown role of \(Pak2\) in \(Nf1^{+/+}\) cells. \(Pak2\) carries out critical functions in cells, as homozygous disruption of the gene is embryonically lethal at a very early stage, and attempts to make a conditionally disrupted \(Pak2\) knockout mouse have been unsuccessful at generating \(Pak2^{flax}\) progeny so far (data not shown). \(Pak2\) shares high sequence homology with \(Pak1\) (\(\sim 77\%\)) \(^{103}\), and is highly expressed in mast cells (data not shown). It is possible that after adoptive transfer of \(Nf1^{+/+}\);\(Pak1^{+/+}\) bone marrow, \(Pak2\) expression or \(Pak2\) kinase activity is increased to compensate for the loss of \(Pak1\).

An analogous result was found in murine MPD studies, where after adoptive transfer of \(Nf1^{+/+}\);\(Rac2^{+/+}\) bone marrow, the levels of Rac1-GTP increased steadily \textit{in vivo} and leukemias developed in these mice (D.W. Clapp, unpublished data). The relative, non-redundant contributions of \(Pak1\) and \(Pak2\) to cellular functions are still unclear for all cell types, and will need to be examined carefully in order to determine if the Pak kinases are important to neurofibroma pathogenesis.

Other reports indicated that overexpression of dominant negative \(Pak1\) in \(Nf1^{+/+}\) Schwann cell lines prevented malignant transformation \textit{in vitro}, leading us to hypothesize that mice with genetic disruption of \(Pak1\) in tumorigenic, \(Nf1\) null Schwann cells would
disrupt neurofibroma formation \(^{161}\). Nonetheless, the results of the genetic intercross of \(Pak1^{-/-}\) mice with \(Krox20\text{Cre};Nf1^{\text{flox/-}}\) also indicated that \(Pak1\) loss in each lineage of the neurofibroma was inadequate for preventing tumor development. In addition, preliminary work in our laboratory using Schwann cells cultured from murine dorsal root ganglia has shown that \(Nf1^{-/-};Pak1^{-/-}\) Schwann cells have increased invasion and proliferation compared to both wild type and \(Nf1^{+-}\) cells, in opposition to the findings of Tang et al. (F.C. Yang and D.W. Clapp, unpublished results). Further investigations of \(Pak1\) and its effects on Schwann cell functions are warranted, as these early findings hint toward a fundamentally different role for \(Pak1\) in regulating Ras signals in the tumorigenic lineage in comparison to the cells of the microenvironment.

As discussed above, the non-hematopoietic portion of the tumor microenvironment provides mast cell growth promoting factors. Since \(Krox20\text{Cre};Nf1^{\text{flox/-}};Pak1^{-/-}\) mice have similar numbers of mast cells within plexiform neurofibromas as \(Krox20\text{Cre};Nf1^{\text{flox/-}}\) mice, it appears that the signaling pathways that control the production of these factors are intact in \(Krox20\text{Cre};Nf1^{\text{flox/-}};Pak1^{-/-}\) mice to fully induce mast cell activation and therefore do not involve \(Pak1\).

As a whole, the experiments utilizing the \(Krox20\text{Cre};Nf1^{\text{flax}}\) model clearly indicate that loss of \(Pak1\) alone cannot prevent the formation of plexiform neurofibromas. Although loss of \(Pak1\) clearly affects \(Nf1^{+-}\) mast cell responses to SCF \textit{in vitro}, we show that the rather specific conditions of those experiments are not duplicated in the complex milieu of differing cellular lineages and various growth factors found in the regions surrounding \(Nf1\) null Schwann cells where neurofibromas originate. Consequently, attempts at using recently published small molecule inhibitors of \(Pak1\) \(^{213}\) as a single
agent to treat $Krox20\text{Cre};Nf1^{\text{lox}}$ mice with tumors as we have done with imatinib would not be recommended. It is more plausible that successful pharmacologic approaches to the treatment of this disease will have to target multiple signaling molecules simultaneously, as the inhibition of a single component of a pathway can likely be compensated for by other molecules activated by one of the other cytokines present in the tumor. Indeed, part of imatinib’s success at ameliorating neurofibroma progression is due to the fact that it inhibits RTKs other than c-Kit, such as c-Abl and PDGFR-β. Therefore, the future of Pak1 as a pharmacologic target in the therapy of neurofibromatosis type I may be relegated to that as an adjuvant therapy as part of a cocktail of rationally designed small molecules.

The role of Pak1 in PDGF-BB and TGF-β mediated signaling in fibroblasts

Under normal conditions, fibroblasts provide structural integrity and synthesize growth factors and extracellular matrix in nearly every tissue system. In addition, fibroblasts are intimately linked with numerous pathological conditions, including arthritis 214, asthma 215, and neoplasia 216, including plexiform neurofibromas 67,68,71. Invading fibroblasts carry out crucial tasks in cancer progression by altering the local extracellular matrix and by providing mitogenic signals to neoplastic cells 217-219. The involvement of Pak1 in fibroblasts has been investigated in numerous publications using transformed fibroblast cell lines and overexpression systems 101. Here, we present for the first time, evidence in a genetic knockout system using primary cells outlining an
important role for *Pak1* in mediating PDGF-BB and TGF-β mediated responses *in vitro* and *in vivo*.

Our results show that Pak1 activity is critical for the coordinated activation of the cytoskeleton necessary for fibroblast migration. In cells stimulated with either PDGF-BB or TGF-β, *Pak1*−/− cells had decreased levels of activated filamin A (Figures 36 and 40), disruptions in F-actin organization (Figures 38h and 42h), and reduced wound healing responses *in vitro* (Figures 35 and 39). Additionally, using an animal model assay system known to induce fibroblast invasion, we demonstrate that the infiltration of fibroblasts *in vivo* is significantly reduced in *Pak1*−/− mice (Figure 45a and 46a). Fibroblast migration and invasion into the provisional matrix of the fibrin clot is an initiating event of wound healing that precedes reproduction and contraction of the extracellular matrix. This invasion step has been linked to PDGF-BB and TGF-β release by activated platelets at the site of the wound. Our results indicate that Pak1 activation mediates the molecular responses necessary for this important physiologic process.

Further experiments with *Pak1*−/− fibroblasts revealed the involvement of *Pak1* in multiple cellular functions. We identified modest but significant increases in apoptosis for *Pak1*−/− cells stimulated with PDGF-BB or TGF-β (Figure 44 c and d). This finding is in contrast to the results of Figure 16, which show that mast cell survival in response to SCF is not affected by loss of *Pak1*. Taken together, these studies demonstrate that *Pak1* anti-apoptotic effects are cell type and stimulus dependent. Interestingly, *Pak1*−/− fibroblasts showed selective functional deficits depending on whether PDGF-BB or TGF-β was used as the stimulus. Loss of *Pak1* resulted in reduced Erk activation and decreased proliferation in fibroblasts stimulated with PDGF-BB (Figure 31 and 32), but
not cells stimulated with TGF-β (Figure 32 and 33). Other reports have utilized RNAi approaches to identify Pak2 as an important non-Smad pathway effector of TGF-β mitogenic signaling in fibroblasts. Our findings indicate that this growth promoting function in response to TGF-β is specific to Pak2. Furthermore, we find that Pak1 null cells have reduced collagen production in response to TGF-β stimulation, but not PDGF-BB (Figure 43). While both growth factors are able stimulate collagen production, Pak1 involvement seems to be unique to TGF-β stimulation.

Idiopathic pulmonary fibrosis (IPF) is a disease that kills 40,000 patients per year and is associated with progressive dyspnea, decreased pulmonary function, and radiographically identifiable pulmonary infiltrates. Based upon the supposed inflammatory etiology of the disease, IPF was traditionally treated with systemic corticosteroids. However, clinical studies have revealed that corticosteroid treatments are ineffective and do not improve survival. Currently, IPF is believed to be the result of overactive fibroblast activation in response to fibrogenic factors released by alveolar epithelial cells following repeated pulmonary microinjury. Two of the most prominently increased cytokines in the lungs of IPF patients include PDGF-BB and TGF-β. Using an established animal model of bleomycin induced lung fibrosis, we found that Pak1−/− mice developed a significantly less severe fibrosis and had decreased amounts of newly synthesized collagen after exposure to bleomycin (Figure 47e and f). However, the magnitude of difference of fibrosis severity between wild type and Pak1−/− mice was not dramatic (~20%), despite the high amount of statistical significance (p<0.0001). This could be due to the fact that following exposure to bleomycin, fibroblasts in the lung proliferate in response to PDGF-BB and TGF-β. However, our
in vitro data indicates that Pak1−/− fibroblasts are deficient in only PDGF-BB mediated proliferation. TGF-β mediated mitogenic responses are intact in these animals and this could account for the only modest improvement in fibrosis in Pak1−/− mice.

In summary, these studies recognize a function for Pak1 in mediating PDGF-BB and TGF-β signaling in fibroblasts. In addition, we demonstrate that Pak1 activates of the actin cytoskeleton leading to cell migration and invasion, an early and critical process of the wound healing response. Finally, we show that loss of Pak1 improves the lung pathology in an animal model of a serious human disease.

Conclusions and future directions

In the studies described here, we identify a role for Pak1 in coordinating molecular signaling in multiple cell types. We report for the first time in a primary cell model that Pak1 activates the MAPK signaling pathway. We establish that Pak1 regulates the characteristic hyperactivation of the MAPK pathway and several associated gain-in-function phenotypes found in Nf1+/− mast cells stimulated with SCF, including proliferation, migration, and degranulation. Surprisingly, we found that the corrections in Nf1 haploinsufficient mast cell functions caused by loss of Pak1 in vitro did not affect the development of plexiform neurofibromas in Krox20Cre;Nf1flx/− mice. The unexpected results of the plexiform neurofibroma studies underscore the unique insight provided by animal models into the complex cell-to-cell interactions underlying tumorigenesis in a manner that in vitro studies cannot replicate. Further experiments utilizing the
The generation of \textit{Krox20Cre;Nf1^{fluox-}} mouse model are critical for validating the proposed biochemical schema generated from our cellular data.

One set of studies with particular relevance to the role of \textit{Pak1} and neurofibroma formation involves the adoptive transfer of \textit{Nf1^{+/-};Rac1^{-/-}} bone marrow into \textit{Krox20Cre;Nf1^{fluox-}} mice. If these mice have interrupted tumor formation, it would provide more evidence that Rac-GTPase signaling in hematopoietic cells during tumor formation employs other downstream mediators in addition to \textit{Pak1}, and that signaling cues from the microenvironment preferentially activate these alternate pathways. In addition, the successful development of a \textit{Pak2} conditional knockout mouse would prove very useful for the study of neurofibroma pathophysiology. The mast cell assays described here be repeated with \textit{Nf1^{+/-};Pak2^{fluox/fluox}} mice, and compared to the results described here using \textit{Pak1^{-/-}} cells to determine if non-redundant functions of the Pak isoforms exist. In particular, it would be of interest to see if \textit{Pak2} null mast cells had changes in survival or maturation, two functions where \textit{Pak1} appears to be non-essential. The generation of \textit{Nf1^{+/-};Pak1^{-/-};Pak2^{fluox/fluox}} mutant bone marrow would be particularly valuable for adoptive transfer into \textit{Krox20Cre;Nf1^{fluox-}} mice for tumor studies similar to those performed here. We hypothesize that transplantation of \textit{Nf1} haploinsufficient hematopoietic cells lacking both Pak1 and Pak2 will delay neurofibroma formation. An additional line of experimentation to follow up on these studies involves the role of membrane bound SCF to neurofibroma formation. Intercrossing the \textit{Krox20Cre;Nf1^{fluox-}} mouse with \textit{Sl/Sl^d} mouse and following plexiform neurofibroma formation in the progeny would provide an easily interpretable method for assessing the contribution of the membrane bound form of SCF to tumor pathology.
In addition, this report demonstrates that Pak1 is necessary for activating various fibroblast functions in response to PDGF-BB and TGF-β. These fibroblast studies point out a potential responsibility for Pak1 in regulating physiologic functions such as wound healing. Keloids are pathologic scars formed by overactive wound healing responses. Experiments utilizing recently developed Pak1 inhibitors could be used in murine models of keloid development, to investigate whether the putative role for Pak1 in wound healing outlined in this work is involved in this disease process. Lastly, we also establish a role for Pak1 in a significant respiratory disease, idiopathic pulmonary fibrosis. Although the decreases in bleomycin induced lung fibrosis are not drastic in Pak1-/- mice, it is unknown what a 20% change in fibrosis severity and collagen content means in relation to overall pulmonary function. Therefore, it would be of interest to compare airway morphometry, resistance, and ventilation/perfusion ratios of lungs harvested from bleomycin treated wild type and Pak1-/- mice.

These studies demonstrate that Pak1 is a key regulator of various cellular functions in both mast cells and fibroblasts by activating multiple pathways, including Ras/Raf/Mek/Erk, p38 MAPK, and actin regulating proteins, in the context of both normal and hyperactivated Ras. We provide novel data that identifies Pak1 as a potential target for therapeutic interventions in fibrotic diseases. Our findings have enhanced the understanding of the molecular underpinnings of neurofibromatosis type 1, providing knowledge into the pathogenesis of this common and debilitating disease. Due to its critical location at the intersection of numerous signaling networks responsible for important biological outcomes, further investigation into Pak1 and related isoforms holds great potential for future researchers and clinicians.
REFERENCES


111. Parrini MC, Lei M, Harrison SC, Mayer BJ. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol Cell. 2002;9:73-83.


Curriculum Vitae

Name: Andrew S. McDaniel

Current Position:

2002-present: Student, M.D./Ph.D. program
Indiana University School of Medicine
Department of Microbiology/Immunology
Advisor- D. Wade Clapp, M.D.

Education

2002: B.S.-Biology, Indiana University, Bloomington IN
2008: Ph.D.- Microbiology/Immunology, Indiana University, Indianapolis, IN

Honors/Awards

Academic Honors Scholarship, Anderson University, 1998-2000
Dean’s List, Anderson University, 1998-2000
Dean’s List, Indiana University, 2000-2002
Winner, Wells Center Summer Student Intern Poster Competition, Indiana University School of Medicine, 2001
Indiana Genomic Initiative Scholar Award, Indiana University, 2002
Winner, Sigma Xi Graduate Student Research Competition, Indiana University, 2006
Best Overall Student Presentation, Department of Microbiology/Immunology Research in Progress, Indiana University, 2006
ASH Merit Award, American Society of Hematology, 2007
Best Overall Student Presentation, Department of Microbiology/Immunology Research in Progress, Indiana University, 2006
SPR Student Research Award, Society for Pediatric Research, 2008

Grants/Fellowships

Indiana Medical Scientist Training Program Fellowship, Indiana University 2002-2004
Principal Investigator- “The role of Pak1 in regulating plexiform neurofibroma formation” Individual NRSA F30 NS060322-01 National Institute of Neurological Diseases and Stroke, National Institutes of Health, 2007-2010

Publications


Abstracts


